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Abstract
An adverse food reaction is defined as clinical symptoms occurring in children, adolescents or adults after inges-
tion of a food or chemical food additives. This reaction does not occur in healthy subjects. In certain individuals is
a manifestation of the body hypersensitivity,  i.e. qualitatively altered response to the consumed food. The disease
symptoms observed after ingestion of the food can be triggered by two pathogenetic mechanisms; this allows
adverse food reactions to be divided into allergic and non-allergic food hypersensitivity (food intolerance). Food
allergy is defined as an abnormal immune response to ingested food (humoral, cellular or mixed). Non-immuno-
logical mechanisms (metabolic, pharmacological, microbiological or other) are responsible for clinical symptoms
after food ingestion which occur in non-allergic hypersensitivity (food intolerance).
Food allergy is considered a serious health problem in modern society. The prevalence of this disorder is varied
and depends, among other factors, on the study population, its age, dietary habits, ethnic differences, and the
degree of economic development of a given country. It is estimated that food allergy occurs most often among
the youngest children (about 6-8% in infancy); the prevalence is lower among adolescents (approximately 3-4%)
and adults (about 1-3%).
The most common, age-dependent cause of hypersensitivity, expressed as sensitization or allergic disease (food
allergy), are food allergens (trophoallergens). These are glycoproteins of animal or plant origine contained in: cow’s
milk, chicken egg, soybean, cereals, meat and fish, nuts, fruits, vegetables, molluscs, shellfish and other food prod-
ucts. Some of these allergens can cause cross-reactions, occurring as a result of concurrent hypersensitivity to food,
inhaled or contact allergens.
The development of an allergic process is a consequence of adverse health effects on the human body of different
factors: genetic, environmental and supportive. In people predisposed (genetically) to atopy or allergy, the devel-
opment of food allergy is determined by four allergic-immunological mechanisms, which were classified and described
by Gell-Coombs. It is estimated that in approximately 48-50% of patients, allergic symptoms are caused only by
type I reaction, the IgEmediated (immediate) mechanism. In the remaining patients, symptoms of food hypersen-
sitivity are the result of other pathogenetic mechanisms, non-IgE mediated (delayed, late) or mixed (IgE mediated,
non-IgE mediated).
Clinical symptomatology of food allergy varies individually and depends on the type of food induced pathogenetic
mechanism responsible for their occurrence. They relate to the organ or system in which the allergic reaction has
occurred (the effector organ). Most commonly the symptoms involve many systems (gastrointestinal tract, skin,
respiratory system, other organs), and approximately 10% of patients have isolated symptoms. The time of symp-
toms onset after eating the causative food is varied and determined by the pathogenetic mechanism of the aller-
gic immune reaction (immediate, delayed or late symptoms).
In the youngest patients, the main cause of food reactions is allergy to cow’s milk. In developmental age, the clin-
ical picture of food allergy can change, as reflected in the so-called allergic march, which is the result of anatomi-
cal and functional maturation of the effector organs, affected by various harmful allergens (ingested, inhaled, con-
tact allergens and allergic cross-reactions).
The diagnosis of food allergy is a complex, long-term and time-consuming process, involving analysis of the aller-
gic history (personal and in the family), a thorough evaluation of clinical signs, as well as correctly planned allergic
and immune tests. The underlying cause of diagnostic difficulties in food allergy is the lack of a single universal lab-
oratory test to identify both IgE-mediated and non-IgE mediated as well as mixed pathogenetic mechanisms of
allergic reactions triggered by harmful food allergens. In food allergy diagnostics is only possible to identify an 
IgE-mediated allergic process (skin prick tests with food allergens, levels of specific IgE antibodies to food aller-
gens). This allows one to confirm the diagnosis in patients whose symptoms are triggered in this pathogenetic
mechanism (about 50% of patients). The method allowing one to conclude on the presence or absence of food
hypersensitivity and its cause is a food challenge test (open, blinded, placebo-controlled). The occurrence of clini-
cal symptoms after the administration of food allergen confirms the cause of food allergy (positive test) whereas
the time elapsing between the triggering dose ingestion and the occurrence of clinical symptoms indicate the patho-
genetic mechanisms of food allergy (immediate, delayed, late).
The mainstay of causal treatment is temporary removal of harmful food from the patient’s diet, with the introduc-
tion of substitute ingredients with the nutritional value equivalent to the eliminated food. The duration of dietary
treatment should be determined individually, and the measures of the effectiveness of the therapeutic elimination
diet should include the absence or relief of allergic symptoms as well as normal physical and psychomotor devel-
opment of the treated child.
A variant alternative for dietary treatment of food allergy is specific induction of food tolerance by intended con-
tact of the patient with the native or thermally processed harmful allergen (oral immunotherapy). This method has
been used in the treatment of IgE-mediated allergy (to cow’s milk protein, egg protein, peanut allergens). 
The obtained effect of tolerance is usually temporary.
In order to avoid unnecessary prolongation of treatment in a child treated with an elimination diet, it is recom-
mended to perform a food challenge test at least once a year. This test allows one to assess the body’s current abil-
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ity to acquire immune or clinical tolerance. A negative result of the test makes it possible to return to a normal diet,
whereas a positive test is an indication for continued dietary treatment (persistent food allergy).
Approximately 80% of children diagnosed with food allergy in infancy “grow out” of the disease before the age of
4-5 years. In children with non-IgE mediated food allergy the acquisition of food tolerance is faster and occurs in
a higher percentage of treated patients compared to children with IgE-mediated food allergy.
Pharmacological treatment is a necessary adjunct to dietary treatment in food allergy. It is used to control the rapid-
ly increasing allergic symptoms (temporarily) or to achieve remission and to prevent relapses (long-term treatment).
Preventive measures (primary prevention of allergies) are recommended for children born in a “high risk” group for
the disease. These are comprehensive measures aimed at preventing sensitization of the body (an appropriate way
of feeding the child, avoiding exposure to some allergens and adverse environmental factors). First of all, the infants
should be breast-fed during the first 4-6 months of life, and solid foods (non milk products, including those con-
taining gluten) should be introduced no earlier than 4 months of age, but no later than 6 months of age. An elim-
ination diet is not recommended for pregnant women (prevention of intrauterine sensitization of the fetus and
unborn child). The merits of introducing an elimination diet in mothers of exclusively breast-fed infants, when the
child responds with allergic symptoms to the specific diet of the mother, are disputable. Secondary prevention focus-
es on preventing the recurrence of already diagnosed allergic disease; tertiary prevention is the fight against organ
disability resulting from the chronicity and recurrences of an allergic disease process.
Food allergy can adversely affect the physical development and the psycho-emotional condition of a sick child, and
significantly interfere with his social contacts with peers. A long-term disease process, recurrence of clinical symp-
toms, and difficult course of elimination diet therapy are factors that impair the quality of life of a sick child and
his family. The economic costs generated by food allergies affect both the patient’s family budget (in the house-
hold), and the overall financial resources allocated to health care (at the state level). The adverse socio-economic
effects of food allergy can be reduced by educational activities in the patient’s environment and dissemination of
knowledge about the disease in the society.
Key words: food hypersensitivity, food allergy, children, adolescence, statement.
Introduction
The “Food Allergy” Working Group of the Polish Society
of Paediatric Gastroenterology, Hepatology and Nutrition
(PTGHiŻDz) presents to the Polish medical community its
position on food allergy in children and adolescents.
Hypersensitivity to consumed food or group of foods,
in infants, children and adolescents as well as adults, is
becoming an increasingly common cause of many individ-
ually different, recurrent or chronic clinical symptoms. This
global health problem, which is becoming increasingly
important in today’s society, has been addressed in exten-
sive medical literature and reports of scientific societies
and institutions involved in health care. In Poland, this prob-
lem is still underestimated, and the only position of a group
of Polish experts was published in 1997. The works of the
editorial team on this document included an analysis of
global literature dedicated to the causal and pathogenet-
ic role of food hypersensitivity in triggering and sustaining
symptoms in sensitive individuals, as well as health effects
and the socioeconomic impact of this hypersensitivity.
The main purpose of this document was to help the
medical community in understanding the appropriate
scale of the phenomenon, and to assist physicians of var-
ious specialties in taking diagnostic and therapeutic deci-
sions as well as preventive measures concerning food
allergy in our country.
The authors are convinced that the information con-
tained in this document will be helpful for parents of the
affected children, as well as for adults with this disorder.
Members of the Working Group held two meetings
devoted to discussion of the theses of the document (April
2006, May 2009). The draft version was also discussed at
a meeting of the Commission for the prevention of Civil-
isation Diseases, the Human Development Committee,
Polish Academy of Sciences (February 2010), and during
the 6th Symposium of the Polish Society of Paediatric Gas-
troenterology, Hepatology and Nutrition, at a session ded-
icated to food allergy (May 2010).
As chairman of the “Food Allergy” Working Group of
the Polish Society of Paediatric Gastroenterology, Hepa-
tology and Nutrition, I give special thanks to all those who
contributed, through their valuable comments, to the
drafting of the final version of this Statement.
Prof. Maciej Kaczmarski MD, PhD
Definition
Clinical symptoms which occur in some people (chil-
dren, adolescents, adults) during eating or after eating
particular food(s) and/or various food additives are
referred to as an adverse food reaction [1].
An adverse food reaction only occurs in people with
signs of individual hypersensitivity. These characteristics
qualitatively change the nature of the body’s biological
response to the consumed food or compounds (sub-
stances) added to food [2].
Food intake (regardless of the type or dose) by per-
sons to whom it is harmful leads to triggering of patho-
genetic mechanisms responsible for the occurrence and
Postępy Dermatologii i Alergologii XXVIII; 2011/5334
Maciej Kaczmarski, Jolanta Wasilewska, Elżbieta Jarocka-Cyrta et al.
dynamics of specific symptoms. This abnormal reaction
to consumed food distinguishes people with hypersensi-
tivity (sick) from healthy subjects [1, 2].
The classification of adverse food reactions of the
European Academy of Allergy and Clinical Immunology
(EAACI) of 1995 was presented in the publication of Brui-
jnzeel-Koomen et al. [1]. In this classification, responses
of the human body to consumed food are divided into
two categories: toxic and non-toxic.
Toxic reactions are always associated with the same
kind of clinical symptoms occurring in all people exposed
to the same consumed food (e.g. contaminated food =
food poisoning).
Non-toxic reactions are attributed to patients with
a qualitatively different response to a food, a specific nutri-
ent or food additive. The pathogenetic mechanisms trig-
gered by undesirable, non-toxic reaction of the body to
consumed food are the basis for classifying these patients
into two groups: those with food allergy and those with
food intolerance [1].
According to the proposed definitions:
– food allergy is a form of adverse food reaction in which
clinical symptoms are triggered and/or modified by the
immune pathogenetic mechanism (IgE-mediated or
non-IgE mediated), 
– food intolerance is a form of adverse food reaction in
which clinical symptoms are triggered and/or modified
by non-immune pathogenetic mechanisms (enzymat-
ic, pharmacological or undefined) [1].
In 2001, members of the European Academy of Aller-
gy and Clinical Immunology (EAACI) and the World Aller-
gy Organization (WAO) proposed a change of the nomen-
clature of allergic diseases [2]. The aim of these changes
was to harmonise the language for allergic diseases used
both in scientific research and medical care for patients,
as well as education. A glossary of the key concepts in
allergy was then developed to optimise their unambigu-
ous understanding by scientists, physicians, patients and
anyone interested in the problems of allergy. The glossary
is available in 24 languages on the website of EAACI. The
proposed allergological terminology has been used in edu-
cational materials dedicated to asthma and allergy, post-
ed on the websites of the WAO and the World Health
Organization (WHO) [2].
The new nomenclature introduced the concept of
hypersensitivity, i.e. reaction of the body to the effect of
a harmful (pathogenic) factor at a dose which produces
no reaction in healthy subjects. Based on this concept,
the originally used term food allergy was replaced by the
term allergic hypersensitivity (IgE-mediated, non-IgE medi-
ated), and food intolerance was replaced by the term
nonallergic hypersensitivity (Table 1) [2].
In 2003, members of the EAACI and the WAO intro-
duced further changes to the allergological nomencla-
ture. According to this nomenclature, the term “food aller-
gy” should be used only in the case of IgE-mediated food
allergy, whereas the term “non-allergic food hypersensi-
tivity” should be used for all responses from the subgroup
of non-IgE mediated immune mechanisms (Fig. 1) [3].
At the end of 2010, a team of experts appointed by
the US National Institute of Allergy and Infectious Dis-
eases (NIAID), in collaboration with 34 professional orga-
nizations, federal agencies and patients’ associations,
published guidelines for diagnosing and treating food
allergies in the United States. The NIAID report described
the current classification of adverse food reactions. The
term “adverse food reaction” is here a broader concept
and includes all pathogenetic mechanisms (immune and
non-immune) responsible for the occurrence of food-
induced symptoms. Depending on the type of immune
mechanisms involved in the response to consumed food,
a distinction was made between “food allergy” and “coeli-
ac disease”, whereas food reaction with involvement of
non-immune mechanisms was named “food intolerance”
(Fig. 2) [4].
The transparency of this classification makes it the
most useful in everyday clinical practice [4]. According to
US guidelines, food allergy is an adverse, reproducible
and repeatable reaction resulting from the body’s immune
response specific to a particular food.
Table 1. Hypersensitivity classification according to modified terminology of atopic and allergic diseases (EAACI, 2001) [2]
Hypersensitivity
Immunologic mechanisms defined or strongly suspected Immunologic mechanisms excluded 
= allergic hypersensitivity = non-allergic hypersensitivity
Pathogenetic mechanisms Pathogenetic mechanisms 
IgE-mediated non-IgE-mediated
Non-atopic hypersensitivity: Atopic • T cell-mediated, e.g. contact 
• Insects stings hypersensitivity dermatitis, coeliac disease
• Helmints • Eosinophil-mediated, 
• Drugs e.g. eosinophilic gastroenteropathy
• Others • IgG-mediated, e.g. allergic alveolitis
• Other
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In this terminology, allergy and allergic diseases mean
all medical conditions resulting from the modified
immune response to a specific allergen. Disease symp-
toms are the result of pathogenetic mechanisms which
are divided into four groups: IgE-mediated, non-IgE medi-
ated, mixed (IgE-mediated and non-IgE mediated), and
cellular [4].
According to the guidelines, this group of symptoms
includes: 1) food-induced anaphylaxis (systemic symp-
toms), 2) food-induced gastrointestinal allergy (immedi-
ate gastrointestinal response, eosinophilic oesophagitis,
eosinophilic gastroenteritis, food-induced proctocolitis,
food-induced enterocolitis, allergy of the oral mucosa), 
3) food-induced skin reactions (acute urticaria, angioneu-
rotic oedema, atopic dermatitis, contact dermatitis, con-
tact urticaria), 4) respiratory symptoms (from the upper
and lower respiratory tract, Heiner syndrome).
These symptoms from various systems may be com-
bined or, more rarely, they can be isolated. Symptoms
from the respiratory system, and in particular Heiner syn-
Immune pathogenetic 
mechanism IgE-mediated
Enzymatic, 
pharmacological, other
T cell mediated, e.g. contact
dermatitis, coeliac disease
Eosinophil-mediated, e.g. 
eosinophilic gastroenteropathy
Other
IgE-mediated, 
e.g. allergic alveolitis
Food hypersensitivity
Non-immune pathogenetic
mechanisms
Fig. 1. Food hypersensitivity (WAO revised nomenclature, 2003) [3]
Allergic food 
hypersensitivity
Non-allergic food hypersensitivity
Immune pathogenetic mechanisms 
non-IgE mediated
Non-IgE
mediated, e.g.
food-protein
induced
enteropathy,
coeliac 
disease
Mixed IgE and
non-IgE
mediated, 
e.g.
eosinophilic
gastroenteritis
Cell mediated,
e.g. allergic
contact
dermatitis
Metabolic, 
e.g. lactose
intolerance
Pharmaco -
logical, 
e.g. caffeine
Toxic, e.g.
scombroid 
fish toxin
Other/
idiopathic
undefined, 
e.g. sulphites
Fig. 2. Types of adverse reactions to food (NIAID classification, 2010) [4]
IgE-mediated,
e.g. acute
urticaria, 
oral allergy
syndrome
Immune mediated (food allergy and coeliac) Non-immune mediated (primarily food intolerances)
Adverse food reaction
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drome, are associated with cellular infiltrates in the lungs
and they are often associated with systemic symptoms
such as abnormal weight gain and iron deficiency
anaemia [4].
In the US classification, the term “food hypersensi-
tivity” was used only to determine the immediate IgE-
mediated gastrointestinal (GI) hypersensitivity [4].
Summary 1
Repeatable and reproducible clinical symptoms, which
occur in some people (children and/or adults) after eat-
ing specific food(s) and various chemical food additives,
are referred to as adverse food reactions.
Adverse food reactions only occur in people with signs
of individual hypersensitivity. These characteristics qual-
itatively change the nature of the body’s biological
response to the consumed food or food additives.
In the terminology currently used in Europe, it has
been suggested to define food allergy as a body’s
response to consumed food, for which an “IgE-mediat-
ed” pathogenetic immune mechanism has been shown.
Food reactions caused by “non-IgE mediated” immune
mechanisms are referred to as non-allergic food hyper-
sensitivity.
According to the US terminology, allergic diseases,
including food allergy, are the result of the body’s abnor-
mal immune response to a specific allergen, where the
pathogenetic mechanisms can be divided into four
groups: IgE-mediated, non-IgE mediated, mixed and cel-
lular. According to this terminology, adverse food reac-
tion is a term for reactions with involvement of immune
mechanisms (including food allergy and coeliac disease)
as well as reactions resulting from various pathogenetic
mechanisms of non-immune origin (most often food intol-
erance).
Epidemiology of food allergy and non-allergic
food hypersensitivity
The World Health Organization (WHO) has recognized
food allergy as a health problem affecting 1-3% of adults
and 4-6% of children, and eight food allergens (called the
“big eight”) were declared the most common cause of
hypersensitivity or allergy and the resulting clinical symp-
toms of food allergy (Table 2) [5, 6].
This was reflected in the guidelines for food safety
contained in the Codex Alimentarius [7]. According to
Sampson, the prevalence of food allergy varies depend-
ing on the allergens present in various food products
(Table 3) [8].
It is estimated that food allergy is most commonly
diagnosed among the youngest children (6-8%) and ado-
lescents (about 3-4%); it also occurs among adults (1-3%).
Allergy to cow’s milk proteins affects approximately 2-3%
of infants and is the most common cause of allergic
symptoms resulting from food intake in this age group
[8-10]. In the last decade, 5 studies have been published
evaluating the prevalence of this allergy in the first year
of life based on the results of a food challenge test. The
prevalence was as follows: Finland – 1.9%, the Isle of
Wight – 2.16%, Denmark – 2.22%, the Netherlands –
2.24%, Norway – 4.9% [11].
Data on the prevalence of food hypersensitivity and
food allergy in the population of children-adolescents and
adults in different countries are therefore heterogeneous
[11-18]. These differences, and the resulting problems in
comparing the results of epidemiological studies con-
ducted in the world, are caused by the methodological
criteria. The most important of these is the selection cri-
terion for the study population, for example, the choice
of the population of a certain age (children, adolescents,
adults), health (population of healthy or sick people, or
those at risk of developing allergies – for example, with
or without positive allergy history), or the use of other
criteria, e.g. taking into account the dietary habits of the
study group, and cultural or ethnic differences. In the
methodology of epidemiological studies it is important
to use a specific research tool (e.g. a survey), and meth-
ods allowing one to obtain objective results (such as skin
prick tests, sIgE, patch tests, challenge test) [11, 12].
The first epidemiological study in Poland dedicated
to these issues was conducted at the Bialystok centre 
and involved a group of infants from the north-eastern
region of Poland [16]. The prevalence of food hypersensi-
Table 2. Foods containing most common allergens sensiti-
zing people according to the FAO Report, 1995 [5]
Cow’s milk 
Egg 
Fish 
Shellfish, molluscs 
Nuts 
Peanuts 
Soy 
Wheat 
Table 3. Prevalence of allergy to various food products in
children and adults [8]
Food Young children [%] Adults [%]
Milk 2.5 0.3
Egg 1.3 0.2
Peanuts 0.8 0.6
Tree nuts 0.2 0.5
Fish 0.1 0.4
Shellfish/molluscs 0.1 2.0
Overall 6.0 3.7
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tivity among infants who received mixed or artificial feed-
ing, verified by immune assays, was estimated at 4.5%,
and the most common foods allergens were cow’s milk
proteins, egg protein and citrus fruits. Among infants who
were exclusively breast-fed, food hypersensitivity was
diagnosed in 0.5% of subjects [16].
In 10 European countries, a randomised telephone
survey was performed in numerically representative
groups of parents, asking about the occurrence of aller-
gies in their children. Based on the responses concerning
8825 children, the prevalence of food allergy was evalu-
ated at 4.7% (90% CI 4.2-5.2). According to the parents’
responses, the largest age group affected by this allergy
was that of children aged 2-3 years (7.2%). The most com-
monly indicated sources of food allergens were milk
(38.5%), fruits (29.5%), eggs (19%) and vegetables (13%).
The prevalence of food allergy varied depending on the
country; it was the lowest in Austria (1.7%) and the high-
est in Finland (11.7%) (Tables 4 and 5) [19].
Surveys concerning the prevalence of food hyper-
sensitivity were also carried out in Poland, among chil-
dren and adults at the centre of Lodz [20, 21] and among
adults in Silesia [22]. The results indicated a high preva-
lence of food hypersensitivity reporting by the respon-
dents [20-22].
Multicentre and longitudinal, and not cross-section-
al, studies are considered the most valuable in the epi-
demiology of allergic diseases. Examples of such studies
are multicentre, international epidemiological studies on
asthma and other allergic diseases in children (Interna-
Table 4. Prevalence of hypersensitivity to selected food allergens* in children in different European countries (reported by
parents) [19]
Austria Belgium Denmark Finland Germany Greece Italy Poland Slovenia Switzerland
Prevalence [%] 1.7 4.9 2.5 11.7 3.0 4.8 3.9 8.3 4.6 3.1
Fish 0.0 4.7 0.0 19.8 4.8 8.3 6.1 1.1 7.0 17.4
Seafood 0.0 2.3 4.5 2.1 4.8 0.0 3.0 2.3 4.7 13.0
Wheat 28.6 9.3 4.5 12.5 19.0 0.0 15.2 6.8 23.3 13.0
Meat 0.0 4.7 4.5 1.0 4.8 10.4 15.2 10.2 9.3 8.7
Eggs 7.1 14.0 0.0 14.6 9.5 27.1 15.2 27.3 27.9 21.7
Milk 28.6 55.8 22.7 41.7 23.8 16.7 33.3 55.7 27.9 34.8
Fruits 50.0 23.3 22.7 35.4 66.7 14.6 27.3 26.1 27.9 26.1
Legumes 7.1 11.6 9.1 7.3 4.8 8.3 0.0 1.1 14.0 8.7
Vegetables 28.6 7.0 27.3 24.0 14.3 8.3 9.1 8.0 4.7 13.0
Nuts 7.1 9.3 13.6 13.5 19.0 2.1 9.1 6.8 9.3 13.0
Others 50.0 18.6 18.2 11.5 23.8 27.1 12.1 18.2 18.6 8.7
*Food reported as elicitors (multiple answers allowed)
Table 5. Prevalence of clinical symptoms of food hypersensitivity in children in different European countries (reported by
parents) [19]
Country Skin Respiratory system Gastrointestinal system Cardiovascular system Other organs
Austria 71.4 14.3 7.1 14.3 21.4
Belgium 68.9 31.1 33.3 0.0 0.0
Denmark 63.6 9.1 27.3 0.0 9.1
Finland 56.3 21.9 49.0 0.0 6.3
Germany 77.3 9.1 27.3 4.5 9.1
Greece 81.3 10.4 20.8 4.2 10.4
Italy 65.6 9.4 28.1 0.0 6.3
Poland 84.6 20.9 15.4 0.0 0.0
Slovenia 79.5 15.9 13.6 0.0 4.5
Switzerland 62.5 25.0 29.2 8.3 4.2
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tional Study of Asthma and Allergies in Childhood –
ISAAC), which have also been carried out at selected aller-
gology centres in Poland [23].
Until 2005, no multicentre study had been conduct-
ed using the same methodology (including the use of
blind placebo-controlled food challenge test), assessing
the epidemiology of food allergy. Such wide-scale
research, both for children and adolescents and the adult
population, have been started in various countries of
Europe and in the world as part of the European multi-
centre research project EuroPrevall (6th EU Framework
Programme). One of the main objectives of this pro-
gramme is to determine the prevalence of food allergy in
infants, children and adults in various countries of Europe
and the world, and to identify the appropriate research
tools for the detection of food hypersensitivity in people
of all ages, to provide information on the economic and
social costs of this disease (including the quality of life of
patients and their families), and to develop regulations
necessary for the implementation of an appropriate strat-
egy to help patients suffering from this clinical problem,
by the policy workers [24].
The centre of Lodz has been enrolled in the Euro-
Prevall project; at this centre, 1260 children aged up to
3 years have been included. It was shown that the preva-
lence of IgE-mediated food allergy in children aged 1-3
years is 2.8%. The diagnosis was made based on med-
ical history, clinical examination, skin prick tests with
food allergens, measurement of specific IgE and the
results of double-blind placebo-controlled food chal-
lenge (DBPCFC). Positive skin tests with food allergens
were found in 27% of subjects; specific IgE antibodies
against food allergens (sIgE) were detected in 26% of
these children, while 55% of the parents of these chil-
dren reported allergic symptoms after eating certain
foods. The most common foods responsible for the
reported symptoms were egg protein (1.7%), cow’s milk
proteins (0.9%), peanuts (0.4%) and fruits (0.4%) (in the
following order: oranges, apples, strawberries, kiwifruits)
[24]. The reported prevalence of allergy to cow’s milk
proteins was lower compared to other epidemiological
studies involving the youngest age group, including the
Polish studies cited below. These results were explained
by the authors with the fact that allergy tests were not
performed in children in infancy (< 1 year old), where
the prevalence of allergy to cow’s milk proteins is the
highest [12-18, 24].
In the same year, a study was also undertaken to
evaluate the prevalence of food allergy in infants and
young children in the agglomeration of Lodz. Data
obtained from a survey were verified by individual per-
sonal history, physical examination, and in some of the
surveyed children also by determination of specific IgE
antibodies against food allergens (sIgE) or skin prick
tests. It was found that 11.7% of the children were
affected by food allergy. This percentage decreased with
age, and at 3 years of age only 6% of patients were
affected [25, 26].
Summary 2
Allergic diseases, including food allergy, are a major
health problem throughout the human population in the
world. Food allergy deserves particular attention because
clinical symptoms may occur already at the youngest age,
even in children fed only naturally (breast-fed). These
symptoms may be predictive of a specific allergic disease
in adulthood.
The prevalence of food allergy varies from country to
country. These differences are conditioned, among other
factors, by the subjects’ age, dietary habits in the evalu-
ated population, cultural or ethnic differences, as well as
the degree of economic development of a given country.
The choice of methodology for epidemiological
research significantly affects the obtained results. The
prevalence of food allergy is higher in surveys than con-
firmed in an objective manner using food challenge tests
or other accepted diagnostic methods.
So far, the few epidemiological studies on the preva-
lence of food allergy carried out in Poland were cross-sec-
tional and involved a specific population or region. Cur-
rent epidemiological and clinical information was collected
in the studies conducted as part of the European research
programme (EuroPrevall), in which the Polish group also
participated; the reported results indicate that the preva-
lence of food allergy in our country among children aged
1 years to 3 years is 2.8%, and the prevalence of food
hypersensitivity in children in infancy is 4.5%. The major
food allergens causally associated with food hypersensi-
tivity in Polish children include allergens from egg pro-
tein, cow’s milk proteins, citrus fruits and peanuts.
In various European countries, the prevalence of aller-
gy to cow’s milk proteins in infancy has been estimated
at 1.9-4.9%.
Type and nature of certain food allergens
Food allergens (trophoallergens) are biological com-
pounds of animal or vegetable origin, mostly water-solu-
ble glycoproteins with a molecular weight of 3-160 kDa
(average 20-40 kDa), which are a part of our daily diet.
Food allergens are divided into two classes based on their
structure and physicochemical properties: class I food aller-
gens are resistant to high temperatures and to the action
of proteolytic enzymes or hydrochloric acid; class II food
allergens are homologous with the glycoproteins of fruits,
vegetables and pollens, and cooking or freezing changes
their allergenicity by destroying their conformational epi-
topes. In the case of some allergens, exposure to high tem-
peratures may increase their allergenicity, e.g. roasting
peanuts, or cooking cow’s milk (Maillard reaction) [27-34].
Consumed food products (theoretically all) or food
additives are a common cause of allergy and/or the
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occurrence of various clinical symptoms (allergic disease)
in children and adults with hypersensitivity [33, 34]. Clin-
ical experience shows that in the same individual, the
process of allergisation and/or symptoms of allergic dis-
ease are often caused by not one but more food aller-
gens [27, 30-34].
Cow’s milk and dairy products, veal, beef
Two groups of cow’s milk proteins are of clinical rele-
vance: casein protein (Bos d8) and whey proteins (α-lac-
talbumin – Bos d4, β-lactoglobulin – Bos d5, bovine serum
albumin – Bos d6, bovine immunoglobulin – Bos d7). Cow’s
milk casein differs from milk casein of other related mam-
mals more than whey proteins. Cow’s milk casein contains
4 fractions: αs1, αs2, β, κ. Patients are often allergic to the
fractions of α-casein (100%) and κ-casein (approx. 91.7%).
Among patients with allergy to cow’s milk protein, in
approximately 80% the allergic reactions are associated
with α-lactalbumin. The percentage of patients who are
allergic to cow’s milk bovine serum albumin (a protein also
found in veal and beef meat) is estimated at 0-88%, but
clinical symptoms after ingestion of a beef or veal meal
occur in about 20% of allergic people [11, 27, 31].
The largest biological and immunological similarities
exist between the proteins of cow’s, goat’s and sheep’s
milk. Compared to cow’s milk proteins, the composition
of proteins in the milk of mare, donkey and camel is more
varied. Camel’s milk, like human milk, contains no β-lac-
toglobulin, a fraction present in the milk of other rumi-
nant mammals. This protein is the cause of allergies
and/or allergic symptoms in about 13% to 76% of patients
[11, 27, 31].
People allergic to cow’s milk may therefore experience
cross-reactions after consuming milk or meat of other
ruminants.
Allergy to cow’s milk proteins is clearly more common
than allergy to beef, assessed at 10-20% among those
allergic to milk. Therefore, total elimination of beef from
the diet of children with allergy to cow’s milk proteins is
not justified in all cases; however, all patients allergic to
beef should temporarily eliminate cow’s milk and its prod-
ucts from the diet [11, 27, 31].
Hen's egg protein – proteins of other birds
Egg protein allergens are among the most common
food allergens. This allergy occurs more commonly in chil-
dren than in adults, and the egg white causes more aller-
gies than the yolk. Egg white is a protein complex con-
taining 23 fractions of possible allergen properties. The
main allergens include ovomucoid (Gal d1), ovalbumin
(Gal d2), ovotransferrin (conalbumin) (Gal d3) and
lysozyme (Gal d4).
The main allergen in the yolk is α-livetin, also present
in blood and feathers of birds. This protein is responsible
for cross-reactions to feather, manure and meat albumin,
not just from chickens but also many other birds. In chil-
dren under 2 years of age with clinically overt sensitivity to
hen's egg proteins, sIgE antibodies are directed mainly
against ovalbumin, ovomucoid and yolk proteins. Allergens
in hen's egg white give cross-reactions to similar allergens
from other birds proteins (hen, turkey, goose, duck, quail,
gull, and others), resulting in the bird-egg syndrome. Quail
egg ovomucoid is also a potent allergen and proteinase
inhibitor; despite this, quail eggs are often incorrectly rec-
ommended in Poland for children allergic to hen's egg aller-
gens [27, 32].
Contact with masked allergens (f.e. proteins of hen's
egg, cow's milk, soy, peanuts), hidden in deli and bakery
goods, confectionery and others products, also creates
a potential possibility of sensitization in individuals pre-
disposed to allergy [28, 34].
In the case of class II allergens, body sensitization
and/or allergic disease occur as a result of their pene-
tration into the digestive tract or respiratory system, lead-
ing to the development of an allergic cross-reaction [28].
Many natural substances or chemicals (food additives)
used in the production, processing and storage of food, or
added to the final product, become the cause of individual
hypersensitivity. Their purpose is to improve the organolep-
tic quality, aesthetics or stability of food products. As an
unintended consequence, they may trigger the patho-
genetic mechanisms of non-allergic hypersensitivity (intol-
erance) and the occurrence of disease symptoms [34].
Cross-reactivity cannot be ignored in the aetiopatho-
genesis of food allergy. The basis for this phenomenon is
widely understood similarity of allergens, especially food
and airborne antigens, and above all common epitopes.
Cross-allergy means the coexistence of clinical symptoms
in a person with simultaneous hypersensitivity to at least
two allergens (oral, inhaled and/or contact allergens)
showing homology of the amino acid sequence, espe-
cially within the epitopes (primary structure of the pep-
tide chain), or when the three-dimensional conformation
of the two protein molecules can bind with their specif-
ic antibody [11].
Recent achievements, mainly in the fields of molecu-
lar biology and immunology, allowed us to understand
that cross-reactions do not result merely from the nature
of allergens (food, inhalation), but the nature of the con-
struction of the main antigens, recognized by the host
immune system, stimulating it to the synthesis of spe-
cific antibodies (mainly IgE). Taking into account the
immune mechanisms of cross-allergy, it can be described
as a phenomenon that only occurs when IgE antibodies,
produced as a result of contact with one allergen, recog-
nize and bind to a protein of similar structure, which orig-
inates from a different allergenic source. The effect of
such reactions leads to individually diverse clinical man-
ifestations of cross-allergy [35, 36]. The phenomenon of
cross-allergy is also illustrated by data contained in Tables
6 and 7 [37, 38].
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Genetically modified foods can be a source of food
(hypoallergenic) with reduced or altered potential to cause
allergy in humans. Such products include rice, tomato, let-
tuce and soybeans. However, their therapeutic-nutrition-
al use in allergic people needs further research [39, 40].
Summary 3
Food allergens (trophoallergens) are biological com-
pounds of animal or vegetable origin, mostly glycopro-
teins with a molecular weight of 3-160 kDa (average 
20-40 kDa), which are contained in the basic food prod-
ucts ingested by humans.
Both food allergens from selected food products
(cow’s milk proteins, chicken egg proteins, meat, fish,
grain products, vegetables and fruits), and chemicals
which are added to them, are a common cause of vari-
ous clinical symptoms in hypersensitive people, more fre-
quently in children than in adults.
In older children and adults, so-called cross-allergy
may occur, which causes allergic symptoms due to con-
current hypersensitivity to food, inhaled and/or contact
allergens.
Conditioning factors and pathomechanism 
of food allergy
Food allergy arises with “failing” tolerance, which is
a kind of immune hyporeactivity of the human body “to
contact” with food allergen(s). In this case, a pathologi-
cal phenomenon contrary to tolerance develops, namely
“food hypersensitivity”. The development of allergic food
hypersensitivity (food allergy), as well as other allergic
diseases, is conditioned by combined genetic factors,
environmental exposure to allergens (environmental fac-
tors) and additional nonspecific factors (adjuvant fac-
tors), such as exposure to tobacco smoke, air pollution,
or infection (Fig. 3) [41-43].
Food sensitization is most common in children in the
youngest age groups (0-3 years). This period of life is
characterised by anatomical and functional immaturity
of the protective barriers of the body (especially in the
digestive tract) and the immaturity of many immune
mechanisms. These conditions may predispose to
increased absorption of food allergens in the body [11].
The above biological predispositions, along with addi-
tional contribution of “supporting” factors (constitutional,
infective and related to environmental hygiene condi-
tions) may represent the triggering mechanism for the
development of food allergy at any age, especially in
childhood [30, 33, 41-43].
The development of food allergy, like any allergic
reaction, occurs in two phases [30, 33, 41-43]. When
a person is predisposed to atopy or allergy (due to
genetic factors), the first step of this process is the pri-
mary contact of the immune system with an environ-
Table 6. Clinical cross-reactivity among animal and plant allergens [37]
Allergen origin Food product Cross-reaction Percentage*
Animal Egg Chicken meat < 5
Cow’s milk Beef/veal Approx. 10
Cow milk Goat milk Approx. 90
Beef/veal Lamb Approx. 50
Fish Other fish species > 50
Plant Peanuts Legumes (except lentil) < 10
Soybean Legumes < 5
Wheat Other cereal grains Approx. 25
Peanuts Tree nuts Approx. 35
Tree nuts Other nuts > 50
*It should be noted that patients frequently have positive PST or RAST results to other members of a plant family or animal species (approx. 80%), 
but this does not correlate with clinical reactivity. Clinical reactivity is typically very food-allergen specific
Table 7. Risk of clinical symptoms during an allergic cross-
reaction [38]
Allergy to: Risk of reaction to: % risk
Cow’s milk Goat’s milk 92.0
Molluscs/shellfish Other seafood 75.0
Fish (salmon) Other fish 50.0
Tree nut (walnut) Other tree nuts 37.0
(Brazil, cashew, hazelnut)
Peanuts Other legumes Approx. 5.0
(peas, lentils, beans)
Grain (wheat) Other grains (barley, rye) 20.0
Latex (latex glow) Fruits 35.0
(kiwi, banana, avocado) 
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Fig. 3. Induction and expression of allergic disease (modification based on [41, 42])
Sensitisation of the organism (usually asymptomatic), 
positive allergic-immune tests (usually IgE-mediated atopic 
response or altered cytokine profile)
One-time (primary) exposure of sensitive
(susceptible) organism to allergen(s)
Allergic disease = impairment of anatomical or functional 
features of a specific organ or system (in which the allergic 
reaction takes place = disease symptoms)
Repeated exposure to specific allergen(s)
Genetic determinants
Environmental factors (allergens)
Adjuvant factors
Table 8. Type and prevalence of pathogenetic mechanisms in hypersensitivity to cow’s milk proteins in children [33, 44, 46]
Mechanism of immune response sensitized to foods Percentage of patients in the studies
according to Gell and Coombs [44] of Chandra et al. [46]
Type I Immediate hypersensitivity 48
Type II Antibody-mediated cytotoxicity 6
Type III Immune complex 10
Type IV Delayed hypersensitivity 18
Mixed type More than one type of reaction 28
mental allergen (food). This contact is “saved” in the
person’s immune memory as sensitization (priming).
This phenomenon is usually clinically asymptomatic.
Repeated exposure to the same allergen in people with
a genetic predisposition to atopy leads to excessive syn-
thesis of sIgE, and in patients with a predisposition to
allergy it causes synthesis of pro-allergic cytokines [30,
33, 41-43]. Sensitization of the body (atopic or allergic) is
a prerequisite for the development of food allergy or oth-
er allergic disease in the case of repeated exposure to the
same allergen. The phenomenon of body sensitization
does not mean, however, that every sensitized person
must become allergic. Some sensitised people do not suf-
fer from allergy; beyond the existing process of sensiti-
zation an allergic reaction is also determined by other
factors (individual and environmental) [30, 33, 41-43].
Immune and allergic pathogenetic mechanisms of the
development of hypersensitivity were described by Gell
and Coombs in 1963 [30, 33, 44, 45]. The frequency of
immune response in patients with allergy to cow’s milk
proteins, taking into account the above pathogenetic
mechanisms, was examined by Chandra et al. The results
of these studies are presented in Table 8 [46].
Studies have shown that the estimated percentage
of IgE-mediated immediate mechanism (type I allergic
reaction) is about 48%. Also other non-IgE mediated
pathogenetic mechanisms play an important role in trig-
gering disease symptoms. In approximately 18-20%, sen-
sitised T-cells were involved in the disease process (type IV
reaction), reactions with the participation of immune com-
plexes (type III reaction) accounted for about 10%, and
cytotoxic reactions (type II reaction) approximately 6%.
Mixed IgE-mediated/non-IgE mediated mechanisms were
responsible for clinical symptoms in about 18% of exam-
ined patients [46].
Hypersensitivity reactions to food additives may
involve various non-immune pathogenetic mechanisms
(enzymatic disorders, pharmacological effects, conduc-
tion disturbances in the central and peripheral nervous
system, release of allergic reaction mediators without the
involvement of a specific allergen, and others) [33, 34].
In older children and adults, cross-allergy may occur
due to simultaneous hypersensitivity to food, airborne
and/or contact allergens [35, 36].
The child can also become sensitized in utero by aller-
gens from foods eaten by the pregnant woman. Similar-
ly, breast-feeding may cause sensitization of the child
with food allergens consumed by the mother and pass-
ing into the breast, and thence into breast milk. This
should explain hypersensitivity symptoms which appear
shortly after birth in some children who are fed only nat-
urally (approx. 0.5%) [11, 47, 48].
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Summary 4
The development of food allergy, like other allergic
diseases, is due to the adverse impact on the human body
of genetic, environmental and adjuvant factors.
The more common occurrence of food allergy symp-
toms in the youngest age is associated with physiological
immaturity of immune mechanisms (delayed immuno-
logical maturation), and the specific morpho lo gical-
immune condition of the gastrointestinal system
(anatomical-physiological immaturity, immaturity of the
body’s protective barriers). These conditions increase the
risk of  the child gastrointestinal mucosa damage by infec-
tion, what promotes the increased absorption of food
allergens from the intestinal lumen into the blood.
The development of food allergy is determined by four
different allergic-immune mechanisms, classified and
described by Gell and Coombs.
It is estimated that the IgE-mediated mechanism
(food allergy) is responsible for about 48-50% of food
hypersensitivity symptoms. In the remaining patients,
food hypersensitivity symptoms are the result of other
pathogenetic mechanisms, non-IgE mediated, mixed (IgE-
mediated/non-IgE mediated) or cellular.
During pregnancy the fetus may become sensitized
in utero to allergens contained in foods consumed by the
pregnant woman. There is also the possibility of sensiti-
zation of the child after birth, in the period of exclusive
breast-feeding. As a result of migration of allergens from
the gastrointestinal tract to the mother’s breast, they can
pass with breast milk to the breastfed infant’s gastroin-
testinal tract. These processes may explain hypersensi-
tivity symptoms seen in a group of children who are fed
only naturally.
Clinical course of food hypersensitivity
Isolated clinical symptoms, or a syndrome of a variety
of symptoms, found in patients with food allergy are the
end result of a specific pathogenetic mechanism, started
by eating harmful food or food additives [8, 49-51].
Clinical symptomatology of food allergy in children
and adults is rich and varied [8, 10, 14, 28, 33, 42, 49-51].
Subjective and objective symptoms can involve only one
organ or system, but much more frequently two or more
organs are involved, and the respective symptoms occur
simultaneously [8, 14, 42, 50].
Clinical symptoms of food allergy are non-specific. Con-
sumption of the same harmful food by different patients
can trigger different clinical symptoms. The time to the
onset of symptoms caused by the same food can also vary.
These differences result, among other factors, from indi-
vidual variability of the effector organ for the allergic reac-
tion, and the type of pathogenic mechanisms involved in
the allergic reaction (immediate, late or mixed) [44-46].
The consumed food should be considered the sole cause
of the disease only when there is a relationship between
its consumption and the reported symptoms, ie when 
its elimination from the diet causes complete  or signifi-
cant relief of clinical symptoms, and its reintroduction
causes the recurrence of the same symptoms [8, 10, 14,
33, 50, 51].
The severity of an allergic disease is determined,
among other factors, by the location of the disease
process (single- or multi-organ), and the clinical course
of the disease can be individually varied in different
patients, even if the site of the allergic process is the same
organ or system [10, 14, 51, 52].
At developmental age, the clinical picture of food aller-
gy may change. Anatomical and functional improvement
of the organs and systems involved in allergic reactions
leads to recovery, i.e. “growing out” of food allergy in some
patients. For others there may be changes in clinical
symptoms and new symptoms of allergic disease may
occur (so-called allergic march or allergic marathon) [11,
53, 54]. Contact with other allergens (airborne or contact),
and also changes in the current target organ of the aller-
gic reaction may play an important role in the
unfavourable dynamics of the disease [8, 41, 50-55].
Hypersensitivity to cow’s milk proteins is a “model”
example of the most common allergic disease in children,
causatively related to the harmful effects of food on the
child’s body. It occurs in about 2-3% of infants and it is
the most common cause of post-feeding discomfort in
this age group [10]. It may cause symptoms of immedi-
ate (IgE-mediated), delayed and late (non-IgE mediated),
or mixed (IgE-mediated and non-IgE mediated) reactions
[8, 14, 18, 46, 48-50, 56-60]. Clinical symptoms of allergy
to cow’s milk proteins are characterized by significant
diversity [10, 11, 14, 59]. The first classification of the clin-
ical picture of allergy to cow’s milk in infants was per-
formed by Clein (Table 9) [56].
Since then, the classic clinical picture of allergy to cow’s
milk and other foods has changed worldwide. Currently
the cutaneous form dominates, with a variety of allergic
disorders, including atopic dermatitis (AD), often with
severe clinical course. The incidence of acute diarrhoea
with subsequent enteropathy, leading to chronic malnu-
trition in young children, has significantly decreased.
Besides of skin manifestations, other common disorders
related to the food hypersensitivity are observed, includ-
ing: impaired motility of the upper and lower gastroin-
testinal tract (gastroesophageal reflux, constipation), 
food-induced inflammation of the small intestine and the
colon (enterocolitis, proctitis, enteropathy), mucosal
eosinophilic infiltration in various organs of gastrointes -
tinal tract. These disorders often manifest themselves 
as chronic or recurrent abdominal pain, especially in 
older children [8, 10, 11, 14, 50, 59, 60].
Children with a respiratory response to the harmful
food may present with wheezing, recurrent symptoms
from the throat, tonsils, larynx, and/or ears, with enlarge-
ment of regional lymph nodes. These disorders are usu-
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ally not associated with fever. The systemic form of food
hypersensitivity may also manifest as chronic malnutri-
tion, an isolated, temporary rise in body temperature, or
iron deficiency anaemia. There are also less common clin-
ical forms such as bedwetting, proteinuria, allergic vas-
culitis, hypertransaminasaemia, neurological symptoms
(migraine) or other psycho-emotional symptoms, and
joint ailments (probably related to food hypersensitivity).
This requires a careful differential diagnosis (Table 10) [8,
10, 59, 61-63].
New proposals for classification of clinical allergy to
cow’s milk proteins take into account the severity of the
disease (Table 11), or the pathogenetic mechanisms 
(Table 12) [8, 11, 14, 50, 59].
In terms of the time between exposure to food and
the onset of allergic reactions, they can be divided into
immediate, delayed and late reactions. Food induced
immediate allergic reactions usually occur within a few
minutes to about 4-6 h after food consumption and are
IgE-mediated reactions. In the European nomenclature,
they meet the definition of food allergy; clinical examples
include anaphylactic shock, gastrointestinal anaphylax-
is, urticaria, Quincke’s oedema, cross-reactions (allergy
to latex and foods), and oral allergy syndrome [8, 18, 28,
50, 64, 65, 66].
Delayed or late food hypersensitivity reactions occur
within a few to several hours after eating the food; these
are non-IgE mediated immune reactions [28, 42, 67-71].
These reactions are mainly mediated by T-cells, and they
Table 9. Clinical forms of allergy to cow’s milk proteins [56]
Gastrointestinal
Skin
Respiratory system/ears
Constitutional
Anaphylactic shock
Other forms (less common)
Table 10. Differential diagnosis of allergy to cow’s milk pro-
teins [10]
• Metabolic disorders • Allergy to other foods
• Anatomical abnormalities
(e.g. hen’s eggs, soy, wheat, fish)
• Coeliac disease • Allergy to other substances
• Enteropathies 
(dust, animal dander, moulds)
• Pancreatic insufficiency • Malignancy
• Non-allergic adverse reactions • Infections
to food (e.g. lactose 
or fructoseintolerance) • Sepsis
Table 11. Clinical forms of allergy to cow’s milk proteins (modification based on [59])
Clinical form CMPA One or more of the following symptoms
Mild or moderate Gastrointestinal symptoms:
• Frequent regurgitation, vomiting
• Diarrhoea, constipation (presence or lack of skin lesions around the anus)
• Blood in the stool
• Iron deficiency anaemia
Dermatological symptoms – atopic dermatitis
General symptoms (anxiety or abdominal colic)
Other symptoms (rare)
Severe* Gastrointestinal symptoms:
• Failure to thrive due to diarrhoea or regurgitation/vomiting
• Loss of appetite/refusal to feed
• Moderate to high loss of blood in the stool
Dermatological symptoms:
• Severe form of atopic dermatitis
• Impaired growth
Respiratory:
• Acute laryngoedema, bronchial obstruction
Other:
• Anaphylactic shock
• Severe anaemia (iron deficiency) 
• Hypoalbuminaemia 
*ALARMING SYMPTOMS!!! immediate referral to a specialist
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are manifested by clinical syndromes with symptoms
from the gastrointestinal tract, often occurring in infants
and young children.
Food protein induced proctocolitis
Proctocolitis is the most common and the mildest type
of non-IgE mediated clinical reaction induced by harmful
foods.
This clinical problem mainly affects infants with food
hypersensitivity, who appear to be healthy, and the only
noticeable abnormality is stools which may contain mucus
and/or blood streaks, with a tendency to anaemia and
reddening of the skin around the anus (perianal intertri-
go, typical of this syndrome). These symptoms occur in
the first months of life. The lack of systemic symptoms
such as vomiting, diarrhoea, or inhibition of weight gain,
is helpful in differential diagnosis from other causes (e.g.
infection, anal fissure). These symptoms are most com-
monly caused by hypersensitivity to cow’s milk, less com-
monly to soy products, and particularly to formula con-
taining hydrolysates of cow’s milk proteins. Identical
symptoms can occur in infants exclusively breast-fed by
mothers eating a general diet. If the child’s symptoms
persist, then they become an indication for the elimina-
tion of (most commonly) cow’s milk, egg white or soy
from the breast-feeding mother’s diet. Continued lack of
clinical improvement, despite the use of such a dietary
intervention in the mother, may indicate the need to con-
sider the appropriateness of continued breast feeding,
and replace it with casein fraction hydrolysate, and in an
extreme situation (persistent bleeding, anaemia), even
an elementary formula (amino acid formula – AAF).
In children fed with milk or soy formula who manifest
persistent symptoms of proctocolitis, leading to anaemia,
cow’s milk protein hydrolysates should be first used ther-
apeutically, and in the case of anaemia and/or dyspeptic
symptoms, an elementary formula should be considered.
These symptoms usually disappear by 2 years of age.
After this period of dietary and pharmacological man-
agement, an attempt should be made to gradually intro-
duce the eliminated foods. During the expansion of the
child’s diet it is recommended to test the stool for blood
content.
Endoscopy of the lower gastrointestinal tract is help-
ful in the diagnosis of this syndrome, as it allows one to
confirm (or rule out) the presence of localised or diffuse
oedematous and erosive lesions of the mucosa, and in his-
tological examination, eosinophilic infiltration and over-
grown lymphoid follicles. Allergic and immune assays (skin
tests, sIgE to food allergens) tend to produce negative
results because the bowel lesions are caused by underly-
ing pathogenic mechanisms of food hypersensitivity which
are non-IgE mediated [8, 10, 28, 49, 50, 66, 72].
Food protein induced enterocolitis syndrome
Clinical manifestation of this syndrome can occur at
any age, but usually the youngest children (in the first
months of life) are affected. The typical symptoms of
inflammation of the small intestine and the colon include
irritability, recurrent vomiting after feeding (within 1 h to
3 h), profuse sweating during or immediately after a meal,
and prolonged diarrhoea. Common symptoms also
include abdominal distension, bloody stools or heavier
bleeding from the lower gastrointestinal tract, and inhib-
ited growth of the child. Microcytic anaemia has been
reported; it may be a manifestation of iron losses as
a result of gastrointestinal bleeding (occult or overt). Iron
treatment does not improve blood cell counts, as long as
the causal factor (harmful food) is not eliminated from
the child’s diet. Hypersensitivity to cow’s milk proteins is
believed to be the main cause of these symptoms. In
about 50% of cases these problems are associated with
the consumption of other foods, containing e.g. soy pro-
teins, cereal proteins, rice, peas, poultry meat. Intake of
harmful foods can cause acute crisis with collapse of the
Table 12. Clinical manifestation of food hypersensitivity
based on the pathogenetic mechanism of the disease [8]
IgE-mediated pathogenetic mechanism
Gastrointestinal tract Oral allergy syndrome
Gastrointestinal anaphylaxis
Cutaneous  Urticaria
Angioedema
Morbilliform rashes and flushing
Respiratory system Acute rhinoconjunctivitis
Bronchospasm (wheezing)
Systemic reaction Anaphylactic shock
Mixed pathogenetic mechanism IgE and cell mediated 
Gastrointestinal Allergic eosinophilic oesophagitis 
Allergic eosinophilic gastroenteritis
Cutaneous   Atopic dermatitis
Respiratory Asthma
Cell-mediated pathogenetic mechanism
Gastrointestinal tract Food protein-induced enterocolitis
Food protein-induced proctocolitis
Food protein-induced 
enteropathy syndromes
Coeliac disease
Cutaneous Contact dermatitis
Dermatitis herpetiformis
Respiratory Food-induced pulmonary 
hemosiderosis (Heiner syndrome)
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child’s general condition (in about 20% of affected chil-
dren) as a consequence of vomiting, diarrhoea, dehydra-
tion, and acidosis. The child’s clinical condition and
appearance suggest a septic process, and an increased
peripheral blood leucocyte count may lead to misdiag-
nosis. Prolonged diarrhoea and vomiting, along with
impaired absorption and digestive functions of the intes-
tine, can lead to symptoms of malabsorption with intesti-
nal protein loss.
Endoscopy of the lower gastrointestinal tract reveals
generalised inflammatory and oedematous lesions of the
mucosa, which in exceptional cases may resemble the
morphology of ulcerative colitis. Biopsy of the large intes-
tine shows diffuse inflammatory lesions with infiltration
of mononuclear cells and crypt abscesses of the mucosa.
The underlying cause of the intestinal lesions is non-IgE
mediated pathogenetic mechanisms of food hypersensi-
tivity [10, 28, 49, 66, 67].
Food protein-induced enteropathy 
This pathology is a consequence of the two above-
mentioned syndromes being unrecognized and inade-
quately treated. Persistent diarrhoea, poor appetite, 
frequent vomiting, bloating and anaemia lead to dis-
turbances in body weight gain. Laboratory signs such
as anaemia, hypoproteinaemia, hypocalcaemia, and oth-
ers, form the whole clinical picture of a child with chron-
ic disorders of digestion and absorption [8, 28, 49, 50,
66, 68, 69].
Allergic eosinophilic oesophagitis; allergic eosinophilic
gastroenteritis 
The clinical picture of food hypersensitivity in children
and adolescents may also include syndromes in which
mixed pathogenetic mechanisms (IgE-mediated and non-
IgE mediated), induced by harmful food, produce symp-
toms overlapping with each other. This group of patholo-
gies in children includes atopic dermatitis, allergic
eosinophilic oesophagitis and allergic eosinophilic gas-
troenteritis. Since the problem of atopic dermatitis seems
to be widely known, the authors focused on the charac-
teristics of the two other syndromes of this group [8, 10,
28, 49, 50, 66].
Both diseases occur in patients from early childhood
to the age of youth. The disease consists in eosinophilic
infiltration of different layers of the wall of the oesopha-
gus, stomach and intestines. The depth of this infiltration
(mucosa, submucosa, serous membrane) correlates with
the severity of the disease [8, 10, 49, 50, 66, 70-72].
Allergic eosinophilic oesophagitis manifests as chron-
ic persistent symptoms of gastroesophageal reflux (nau-
sea, vomiting with blood), dysphagia and epigastric pain
in the absence of improvement after conventional anti-
reflux therapy [66, 70, 71, 73].
With a negative result of pH-metry, the diagnostic
process consists in taking sections from the oesophageal
mucosa and finding eosinophilic infiltration in these sam-
ples (10-20 eosinophils per high-power field). The treat-
ment involves a comprehensive approach: elimination of
the harmful food and the use of anti-inflammatory drugs
(steroid therapy, antileukotriene drugs) [66, 70, 71, 73].
Allergic eosinophilic gastroenteritis can also occur in
infancy and may be a significant cause of weight gain and
growth disturbances. Abdominal pain, vomiting with
blood, blood in stool and intestinal protein loss syndrome
are typical symptoms of this disease in older children.
Atopic mechanisms of the disease (positive tests for IgE
antibodies) are found in approximately 50% of these
patients. It must be noted, however, that the pathogen-
esis of this disease is mixed and also involves non-IgE
mediated and cellular (T-cell) mechanisms. The correla-
tion of positive allergy tests with the effects of elimina-
tion of potentially harmful foods, which include milk pro-
tein, soy, cereals, egg white, and others, is usually low 
[10, 66, 73].
The lack of clinical improvement after 3 to 8 weeks of
using an elimination diet is a basis for introducing an ele-
mentary diet in patients of both groups; this diet should
continue for several months. After this period it is rec-
ommended to perform follow-up organ biopsy to evalu-
ate the severity of eosinophilic infiltration. An improve-
ment in the morphology of the intestinal mucosa allows
one to continue treatment with an elementary diet, with
the introduction of one new food every 2 weeks, starting
with fruits or vegetables [66].
Some (naturally) breast-fed babies may also exhibit
symptoms of food hypersensitivity as early as in the first
hours or days of life after birth. These reactions may have
a violent clinical course. As mentioned above, the cause
triggering the disease symptoms are allergens penetrat-
ing through blood and lymph vessels from the gastroin-
testinal tract of the nursing mother to her breast, and
then into the infant’s body, along with the consumed milk.
Clinical manifestation of allergy in these children is indi-
vidually varied and it does not differ in the nature of
symptoms from symptoms reported in artificially fed chil-
dren with food hypersensitivity [47, 48].
Summary 5
The clinical picture of food hypersensitivity in children
and adults represents the great variety of the symptoms
that may affect a single organ (system) or multiple organs
(systems). Simultaneous multi-organ (multi-system) man-
ifestations are more common.
In food hypersensitivity, both the group of associat-
ed clinical symptoms and each symptom in isolation are
the end result of IgE-mediated, non-IgE mediated, mixed
or cellular pathogenetic mechanisms, triggered by the
consumption of harmful food, cross-allergy or food addi-
tives.
The variety of symptoms triggered by the sensitising
food, as well as their potential number, became the basis
for classification into specific “clinical forms of food hyper-
sensitivity”. As with allergy to cow’s milk protein, hyper-
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sensitivity to other foods can also be divided into classic
and less common clinical syndromes associated with this
disease.
At developmental age the clinical picture of food aller-
gy can vary with age (so-called allergic march), which
results from anatomical and functional improvement of
vital organs affected by the harmful allergen (food).
Food allergy diagnostics
The diagnosis of food allergy is a complex, long-term
and time-consuming process, involving analysis of the
atopic/allergic personal and family history, a thorough
analysis of clinical signs, as well as correctly planned addi-
tional tests [79-96].
The underlying causes of difficulties in diagnosing
food hypersensitivity include complex pathogenetic mech-
anisms (immune, non-immune, mixed) responsible for
disease symptoms, and biological characteristics of anti-
gens, which, after digestion in the gastrointestinal tract,
may become a source of new antigens (neoantigens). Due
to these causes, there is so far no simple, inexpensive
and sensitive laboratory test which would allow clear
identification of the main causative factor of food aller-
gy [74, 76-78].
The commonly used methods and laboratory tests are
mainly intended for diagnosing the cases of food hyper-
sensitivity in which IgE-mediated pathogenetic mecha-
nisms are involved; they represent about 50% of patients.
For the diagnosis of other pathogenetic mechanisms of
food hypersensitivity, more complex, technically difficult
and time-consuming techniques and methods are used,
available primarily in specialised clinical centres and
research laboratories [8, 33, 42, 50, 66, 79-96].
The first stage of diagnostics is to collect the patient’s
history in order to determine the beginning and type of
complaints, their organ location, evolution and dynam-
ics associated with the growing process of the affected
child. To complete the history, a physical examination is
performed, including an assessment of the general con-
dition, organ abnormalities, as well as the presence or
absence of constitutional features of allergy [8, 28, 42,
50, 74, 84].
Allergological-immune assays are used in the diag-
nostics of food allergy to confirm or rule out atopic (IgE-
mediated) mechanisms as the cause of the clinical symp-
toms. In this regard, we have the ability to determine
specific IgE (sIgE) in the serum. We also use skin tests
with food allergens (commercial, native), and airborne
allergens [8, 11, 18, 28, 42, 50, 60, 77, 84-88, 93, 96].
Prick skin tests (PST) are typically performed using
the commercial extracts of antigens; they are a rapid,
inexpensive method for detecting IgE antibodies on the
surface of the mast cells of the skin. A negative result
indicates the lack of participation of these antibodies in
the IgE-mediated pathogenetic mechanism of food-
induced allergy in the diagnosed patient. The negative
predictive value of these tests is 90%. A positive result of
the test (wheal diameter of > 3 mm, compared to a neg-
ative control test) does not clearly confirm the diagnosis
of food allergy (30-40% positive predictive value); how-
ever, it confirms sensitization to the allergen (food) test-
ed. In fact, a positive result of the test is not an equiva-
lent of the clinical reactivity of the body, and the wheal
diameter does not correlate with the severity of the dis-
ease [50]. Such a result must be confirmed in a food chal-
lenge test [50, 66]. Often the definitive diagnosis is made
by correlating the positive results of the tests with infor-
mation from the patient’s history and analysis of the dis-
ease symptoms. The authors at various centres assessed
the correlation between wheal diameter and the likeli-
hood of the occurrence of clinical symptoms after inges-
tion of a sensitising food [28, 59, 77, 85, 96]. According to
Sporik et al., wheal diameters are as follows: for cow’s
milk proteins > 8 mm; for egg white protein > 7 mm; for
peanuts > 8 mm [85]. The following issues were discussed
in the commentary on these studies: the varying wheal
diameter for commercial allergens depends on allergens'
different sources, and relates on the study population
dietary habits, place of residence, and race. Skin tests
with commercial allergens and fresh products (native
tests) may be the cause of an extremely rare adverse reac-
tion during the test; the risk of its occurrence increases
when native allergens are used [92].
The second method for determining the IgE-mediat-
ed pathogenetic mechanism in food allergy is the deter-
mination of specific antibodies (sIgE) in the serum, direct-
ed against specific allergens (foods) – Immuno CAP
system. This test is more expensive than SPT [74, 77, 84,
86-88, 92-96].
A positive result of the sIgE test, falling within the range
of values for class 2 of e.g. a CAP assay (0.7-3.5 kU/l) in a per-
son without clinical symptoms, also only proves sensiti-
zation [74, 77, 84, 93]. In this case, the procedure is the same
as for the interpretation of skin tests – a food challenge 
test determines the diagnosis. Also for this test were 
established the positive predictive values of specific 
antibodies (sIgE) for which there is 95% likelihood of 
clinical response after ingestion of a specific food (Table 13)
[77, 86-88, 96].
A new method for detecting allergen-specific IgE anti-
bodies is the ISAC assay (Immuno Solid-phase Allergen
Chip). It is a combination of the latest achievements in
the research on the structure of allergens and biochip
technologies and is based on the use of allergens of
a defined molecular structure (pure allergens). This allows
the determination of sensitization to individual allergenic
proteins contained in the mixture of allergens (allergen
extract), as well as precise identification of molecules that
cause allergic reactions (component-resolved diagnosis,
CRD). The advantage of this test method over the other
assays previously used in food allergy diagnosis has not
been documented until now. There are also no studies
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comparing the sensitivity and specificity of this method
compared to the food challenge test [11, 88].
It seems that the described method will be applied
primarily in the diagnosis of cross-allergy where it is
important to determine the profile of cross-reacting sen-
sitizing allergens. The previously used extracts show aller-
gen instability and contain trace amounts of specific aller-
gens, which affects the diagnostic effectiveness of these
methods. The currently introduced methods will allow
one to detect more accurately which of the allergens con-
tained in the consumed food causes the patient’s aller-
gy, considering that each patient responds with an indi-
vidual clinical response to allergens contained in the same
food product [88, 94].
In conclusion, a negative result of these tests in a per-
son presenting with symptoms is a basis to conclude that
the disease symptoms are not the result of an IgE-medi-
ated response induced by the harmful food. They are
probably a result of triggered non-IgE mediated patho-
genetic mechanisms, and possibly other coexisting caus-
es of the disease (see Table 10) [10, 28, 33, 50, 77, 84].
In some conditions (atopic dermatitis, eczematous
lesions, gastroesophageal reflux, eosinophilic oesophagi-
tis, food-induced enterocolitis), when a food hypersensi-
tivity reaction triggered by a cellular, non-IgE mediated
pathogenetic mechanism is suspected, then diagnostic
patch skin tests (PST) are performed [11, 89, 90, 92, 95,
96]. This test, which involves occlusive application of
a food allergen to the skin (ideally for 48 h), allows one
to detect or rule out a late cellular response, assessing
skin reaction (the number of follicles, not erythema) 48 h
and 72 h after the application of the allergen. Patch skin
tests in conjunction with specific IgE antibody concen-
tration assay can detect most cases of sensitization to
food allergens, especially milk and egg white. A weakness
of this test is the lack of standardisation of this test
method and the divergent opinions of allergists, which
makes the predictive value of PTS a subject of dispute
[94]. Other laboratory tests to confirm or rule out aller-
gic-immune reactions type II, III and IV according to Gell-
Coombs, due to the required effort and high cost, are per-
formed in highly specialised immunology and allergology
laboratories [4, 11, 18, 33, 42, 66, 75, 84, 89, 90, 92, 95,
96]. According to the authors of the EAACI and WAO doc-
ument, the presence of specific food antibodies in the IgG
class (sIgG) in the patient’s serum has no diagnostic sig-
nificance in food allergy, but only indicates previous expo-
sure of the body to a given allergen (food) [3, 11]. Elevat-
ed sIgG4 concentrations may indicate the ongoing
process of acquiring tolerance to previously harmful food
in patients with IgE-mediated food allergy [11].
A method allowing one to clearly determine the exis-
tence of food hypersensitivity, or lack thereof, as well as
to confirm the reliability of the tests described above, is
the result of bioassay challenge with the suspected food
(Tables 14 and 15) [74, 79-83, 96].
This test is crucial in demonstrating the relationship
between a consumed food and clinical symptoms that
occur as a result of a specific pathogenetic mechanism
of the allergic reaction. These mechanisms determine the
approximate time of occurrence of symptoms, and the
time elapsing after the intake of the harmful food (imme-
diate, delayed, late symptoms) [8, 50, 66, 77, 84]. This
test, depending on the patient’s age, is done in two ways:
an open challenge test (up to 3 years old), or a blind food
challenge test, using placebo (single-blind placebo con-
trolled food challenge test – SBPCFC; double-blind place-
bo-controlled food challenge – DBPCFC). Patients receiv-
ing anti-allergic drugs or antihistamines should eliminate
them for at least 72 h (or more, depending on the type of
drug) before the food challenge test. In a blind challenge
test, the patient receives the food suspected to cause the
adverse effects, in a masked form, alternately with place-
bo. It is started from the initial dose for a given food and
continues in increasing doses to the amount normally
consumed. In order to avoid a shock reaction, a lip test is
performed before oral administration of the tested food
[91, 96]. If the patient has a shock reaction or there is
a risk of such a reaction during the challenge (e.g. in
patients with Quincke’s oedema and oral allergy syn-
drome [OAS]), the test should always be performed in
a hospital ward (specialist office), in the presence of
a doctor and a nurse, in a room where lifesaving equip-
ment and drugs are readily available (intubation kit, oxy-
gen, auto-syringe with epinephrine) [66, 77, 84]. The esti-
mated time of reaction after food ingestion, and thus the
time of observation of the patient during a challenge test,
depends on the clinical manifestations of allergic disease
and is longer in gastrointestinal disorders (e.g. eosinophilic
oesophagitis, eosinophilic gastroenteritis). According to
Nowak-Wegrzyn, patients with symptoms of allergic
inflammation of the gastrointestinal tract, after deter-
mining the challenging ingested dose, equal to 0.15-
0.3 g/kg body weight (the dose should not exceed 3 g of
protein or 10 g of the tested food), receive the prepared
food sample over 45 min, in 3 portions [66]. If the patient
does not experience any symptoms within 4 h after the
first administration of the food, he/she should receive
Table 13. Food-specific IgE levels that give 95% likelihood
of reaction [8, 9, 77]
Allergen sIgE level [kIU/l]
Cow’s milk (< 2 years of age) ≥ 5.0
Cow’s milk (> 2 years of age) ≥ 15.0
Eggs (< 1 year of age) ≥ 10.9
Eggs (> 1 year of age) ≥ 13.2
Peanuts ≥ 14.0
Nuts ≥ 15.0
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a second dose, and observation is continued for 2-3 h.
The challenge test is performed in a hospital, under med-
ical supervision, with readily available rescue facilities in
case of an anaphylactic reaction. According to Nowak-
Wegrzyn, due to the possible occurrence of delayed or
insidious symptoms, this observation may have to 
be extended up to a few days. An open food challenge
test should be discontinued immediately when any aller-
gic symptom occurs (sneezing, runny nose, cough, 
vomiting, etc.), and the patient should be observed for
a few hours [66].
In the initial diagnosis of atopic dermatitis, when food
hypersensitivity is suspected to be a contributing factor
in the aetiopathogenesis, it is proposed to eliminate the
harmful food for a period of 2 weeks. After this period,
the food should be re-introduced under medical supervi-
sion. Skin symptoms, which commonly occur in a posi-
tive challenge test, may be associated with gastroin-
testinal or respiratory symptoms [66].
For procedural reasons, double-blind, placebo-con-
trolled tests should be performed in a hospital ward, in
a diagnostic laboratory specialising in the preparation
and masking of the samples. This rule also applies to
open-label trials if there is a likelihood of an anaphylac-
tic reaction in a child with mild to moderately severe clin-
ical hypersensitivity (positive results of immunological
tests for the presence of specific IgE antibodies). These
tests should always be performed in a hospital, until the
results of PTS and/or sIgE indicate a reduced respon-
siveness of the body to an initially harmful allergen [10].
Open-label tests can also be performed in a doctor’s
office, provided that the patient is not at risk of shock
reaction (negative results of allergic-immune tests in IgE
class with certain environmental allergens). This test can
then be continued at home [59, 79-83].
The likelihood of a reaction in the challenged child can
be predicted based on serum sIgE levels. According to pre-
vious studies, there is a high probability of such reaction
and thus no indications for a challenge test in children
with the following levels of serum sIgE against proteins:
cow’s milk > 15 kIU/l, chicken egg > 7 kIU/l, peanuts 
> 14 kIU/l. In the youngest children (up to 2 years of age)
serum sIgE concentration thresholds are different: chick-
en egg white > 2 kIU/l, cow’s milk proteins > 5 kIU/l 
[8, 9, 50, 66, 77, 85-88].
In order to facilitate and streamline the diagnostic
process of food hypersensitivity, various clinical centres
have developed many procedures (diagnostic algorithms)
including a food challenge test. The differences in food
challenge tests mainly concern the choice of food, selec-
tion of the initial dose and subsequent doses, food mask-
ing, and methodological procedure [79-84].
Table 15. Indications after double blind placebo controlled food challenge [80, 83]
Recommendations Food challenge result
Elimination diet reccommended Allergen/positive result (+) Placebo/negative result (–)
Challenge repeat reccomendation Allergen/positive result (+) Placebo/positive result (+)
No indications for a diet Allergen/negative result (–) Placebo/negative result (–)
No indications for a diet Allergen/negative result (–) Placebo/positive result (+)
Table 14. Types of oral food challenge [96]
Type of challenge Food administration method Comment
Open-label Food in the natural form Recommended in infants
Positive result in 50% confirmed by DBPCFC
Single-blind placebo-controlled Hidden food, masked appearance, colour, Usually sufficient for clinical purposes
food challenge (SBPCFC) taste and smell (in capsules, in liquid 
or solid form, in other foods)
The patient is not informed 
about the type of food fed
Double-blind placebo-controlled Food hidden, masked appearance, Diagnostic “gold standard”
food challenge (DBPCFC) colour, taste and smell (as above) A technique recommended for research purposes,
The patient, nurse and doctor enables results from different centres
are blinded to the tested food to be compared
The food and placebo are prepared 
and coded by a third person
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Niggemann proposed a diagnostic algorithm for food
hypersensitivity with an open and a blind challenge tests
interpretation, and Vandenplas developed diagnostic and
dietary guidelines for children with allergy to cow’s milk
proteins, artificially or naturally fed (Table 16 [80], Tables
17-20 [10]).
In various informational materials, available mostly
on the Internet, patients with food hypersensitivity are
encouraged to use other diagnostic tests, such as the fol-
lowing: determining the concentrations of specific IgG
antibodies (sIgG), microscopic evaluation of blood cells
after exposure to the food, chemical analysis of hair, kine-
Table 16. Interpretation of the results of food challenge tests [80]
Open food challenge Open food challenge Open food challenge
Positive challenge result (+) Positive challenge result (+) Negative challenge result (–)
Immediate type of allergic Delayed and late phase of allergic reaction
reaction (IgE-mediated)
Recommended Double-blind placebo-controlled food challenge No indications for a diet
an elimination diet (DBPCFC)
Positive challenge result (+) Negative challenge result (–)
Recommended an elimination diet No indications for a diet
Table 18. Diagnosis and management of cow’s milk allergy in formula-fed infants, severe symptoms (modification based
on [10])
Suspected allergy to cow’s milk protein (CMP)
Formula-fed children/severe symptoms
Stage 1 Clinical assessment and family history
Consider performing skin tests or patch tests to cow’s milk protein
Blood tests – total IgE, specific IgE
Stage 2 Refer the child to a specialist
In the meantime an elimination diet with AAF formula for 2–4 weeks
Stage 3 Improvement No improvement
Challenge test at a specialist clinic Further diagnostics at a specialist clinic
Table 17. Diagnosis and management of cow’s milk allergy in formula-fed infants, mild or moderately severe symptoms
(modification based on [10])
Suspected allergy to cow’s milk protein (CMP)
Formula-fed children/mild or moderately severe symptoms
Stage 1 Clinical assessment and family history
Consider performing skin tests or patch tests to cow’s milk protein
Blood tests – total IgE, specific IgE
Stage 2 Elimination diet
Stage 3 Improvement No improvement
Open-label challenge test based on the results Elimination diet with an AAF formula
of IgE assay. Administration of milk formula or return to the supply of milk in the diet
under supervision of a physician
Stage 4 Recurrence of symptoms No symptoms
Use the elimination diet Return to cow’s milk
until 9-12 months of age, supply in the diet
for at least 6 months
Stage 5 Repeat the challenge test Follow-up
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Table 19. Diagnosis and management of cow’s milk allergy in breast-fed infants, mild/moderately severe symptoms (modi-
fication based on [10])
Suspected allergy to cow’s milk protein (CMP)
Breast-fed children/mild or moderately severe symptoms
Stage 1 Clinical assessment and family history
Stage 2 Continue breast-feeding
Eliminate cow’s milk (and eggs) from the mother’s diet for 2-4 weeks
Administer calcium supplementation 
Stage 3 Improvement No improvement
Re-introduce cow’s milk to the Return to normal diet in the mother 
mother’s diet and consider other causes (differential diagnosis)
Stage 4 Symptoms No symptoms
Maintain the elimination Re-introduce eggs to the 
diet in the mother plus mother’s diet
calcium supplementation
Stage 5 After breast feeding, Follow-up
introduce an eHF formula 
in place of the mother’s milk.
CMP free solid foods until 
9-12 months and for
at least 6 months
Table 20. Diagnosis and management of cow’s milk allergy in breast-fed infants, severe symptoms (modification based
on [10])
Suspected allergy to cow’s milk protein (CMP)
Breast-fed children/severe symptoms
Stage 1 Clinical assessment and family history
Stage 2 Refer the child to a specialist for diagnostic tests and treatment
In the meantime, eliminate cow’s milk from the mother’s diet and use calcium supplementation 
siology, iridology, electrodermal tests (BICOM) and oth-
ers. These methods have no scientifically proven diag-
nostic value and are not recommended by scientific soci-
eties and other competent scientific and clinical
organisations, dealing with the problems of food hyper-
sensitivity [3, 94, 96].
Summary 6
The diagnosis of food allergy is a complex, multistep
and time-consuming process. It includes analysis of the
allergic history (personal and in the family), detailed exam-
ination of the patient and analysis of the existing clinical
symptoms, and interpretation of well-planned allergic
immune tests.
The underlying difficulties in the diagnosis of food
hypersensitivity include the complex pathogenetic
immune mechanisms – IgE-mediated, non-IgE mediated,
mixed or cellular – responsible for the observed symp-
toms.
Due to these mechanisms, so far there is no univer-
sal test for diagnosing food hypersensitivity, i.e. a single
test, inexpensive, sensitive, easy to perform and clearly
identifying the causative agent in food allergy or hyper-
sensitivity.
The commonly used methods for the determination
of specific IgE in the blood and skin tests (skin prick tests
with food allergens) are used primarily for diagnosing food
hypersensitivity, in which solely an IgE-mediated patho-
genetic mechanism is involved (food allergy according to
the European nomenclature). This is possible in only about
50% of patients with this hypersensitivity, in whom pos-
itive results of such tests confirm the causal factor of the
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disease (harmful food). In the remaining patients, the
results of these tests are usually negative, because their
clinical symptoms of food hypersensitivity are triggered
by non-IgE mediated pathogenetic mechanisms, which
are not detectable using the diagnostic methods
described above.
The method allowing definitive confirmation of the
presence and type of food hypersensitivity, and the causal
relationship between the harmful food and the clinical
symptoms (confirmed or ruled out) is a challenge test
with the suspected food. The time interval from food
administration to the onset of disease symptoms in a pos-
itive test indicates the pathogenetic mechanisms respon-
sible for the clinical symptoms in this disease (immedi-
ate, delayed, late).
Dietary treatment of food hypersensitivity
Three important issues related to the elimination diet
are the subject of scientific and clinical considerations:
– is the elimination diet, when strictly adhered to, the
proper method of treating food hypersensitivity?
– does this treatment accelerate the process of recovery
(“outgrowing the food allergy”) and does it eventually
mean restoring or acquiring tolerance to the originally
harmful food?
– is the elimination diet useful or can it be useful in the
prevention of food hypersensitivity, and in the broader
sense, of atopic and allergic diseases?
Food hypersensitivity is a clinical condition in which
harmful food is the major cause of the disease. An elim-
ination diet as a causal treatment of food allergy is often
the primary, and sometimes the only way to treat this dis-
ease [8, 10, 14, 28, 32, 33, 50, 51, 59, 66, 97-105]. Elimina-
tion consists in the temporary removal of the harmful
food from the patient’s diet, with the introduction of nutri-
tionally equivalent substitute ingredients, in place of the
eliminated food (group of foods). Infants with mild or
moderately severe allergy to cow’s milk should first use
an elimination diet for two weeks to establish the initial
diagnosis. In children with atopic dermatitis or allergic
symptoms from the gastrointestinal tract, the initial elim-
ination period should be extended to 4 weeks [10]. The
aim of this procedure is to “silence” the allergic immune
reaction, to allow regeneration of the gastrointestinal
mucosa, and to improve its digestive and absorption func-
tions. The measures of the effectiveness of a therapeu-
tic elimination diet and use of the milk replacement exten-
sively hydrolysed formula (eHF) include the following:
complete or partial resolution of clinical symptoms,
improved general condition and normal physical devel-
opment (weight gain, growth) and psychomotor devel-
opment of the treated child [8, 10, 50, 66, 97-105].
The period of using the elimination diet in the treat-
ment of food hypersensitivity is individually varied. The
period of using this diet is determined based on the fol-
lowing: the child's age at the time of the diagnosis, the
type of food allergy (primary, secondary), the form of clin-
ical hypersensitivity (single-organ or multi-organ), patho-
genetic mechanism (IgE-mediated, non-IgE mediated,
mixed, cellular), positive family history of atopy/allergy
and previously used treatment of the disease, including
dietary measures (any kind of diet/no previous dietary
treatment) [33, 95-100].
To meet the expected therapeutic requirements, the
individually selected elimination diet must be adjusted for
the patient’s age (qualitatively and quantitatively balanced).
It should take into account the type of eliminated food or
group of foods, stage of the disease (severity) and the esti-
mated period of medicinal use of the diet [95, 96, 97-102].
Patients highly sensitive to the causative allergen, e.g. with
atopic dermatitis and allergy to cow’s milk proteins, should
avoid contact with allergens through the skin or by inhala-
tion (e.g. vapours of boiled milk), as well as contact with
milk products from other ungulate ruminants [11].
Milk and dairy products, chicken egg proteins, meat
and vegetable proteins are basic nutritional products for
both children and adults. When we eliminate such prod-
ucts (usually cow’s milk and dairy products) from a young
child’s diet, then milk replacement products containing
a highly hydrolyzed fraction of casein or whey proteins of
cow’s milk (eHF) should be used as a substitute for the
eliminated protein. In the case of unacceptable taste of
the milk replacement formula, lack of clinical improve-
ment indicating a possibility of sensitization to the ther-
apeutic-nutritional product, or signs of malnutrition, Van-
denplas recommends considering the introduction of an
elementary formula (AAF), while other authors recom-
mend a soy protein formula (SF) [10, 59, 60, 66, 97-100].
In hypersensitivity to other food proteins (animal, veg-
etable), a hypoallergenic diet should be used with sub-
stitution of the eliminated proteins with other harmless
protein products, and with supplementation of macronu-
trients (especially calcium) as well as trace elements and
vitamins [10, 50, 97-100]. WAO guidelines recommend
mandatory use of a therapeutic-nutritional milk replace-
ment formula (eHF) in children with allergy to cow’s milk
proteins to the age of 2 years. In older children the use
this type of formula depends on clinical indications and
the decision of the treating physician [11].
Soybean formulas, which can be used in the treat-
ment of certain clinical forms of food allergy, may repre-
sent a therapeutic-nutritional alternative for some of
these patients. Contraindications to these product include
age less than 6 months and food-induced enterocolitis or
enteropathy in young children. Other reasons for restric-
tions on the use of such formulas may also be cross-
reactions to cow’s milk proteins allergens, observed in
about 10-14% of patients with primary hypersensitivi-
ty to these allergens, as well as the adverse effects of
phytates and phytoestrogens contained in soya beans
[10, 72, 103, 104].
For the last 20 years, there has been an increasing
number of clinical reports, including in Poland, on the pos-
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Table 21. Treatment of milk allergy according to the current recommendations in different countries (WAO) [11]
Breastfed
Formula-fed
Partially 
hydrolyzed 
formula (pHF)
Extensively 
hydrolyzed 
formula (eHF)
ESPACI/ESPGHAN 1999
Høst A. Dietary products 
used in infants for treat-
ment and prevention of
food allergy. Joint State-
ment of the ESPACI Com-
mittee on hypoallergenic
formulas and ESPGHAN
Committee on nutrition.
Arch Dis Child 1999; 81:
80-4
AAP 2000
American Academy of 
Pediatrics. Committee on
Nutrition. Hypoallergenic
infant formulas. Pediatrics
2000; 106: 346-9
No. Scientific Society 2007*
Vandenplas Y, Koletzko S, 
Isolauri E, et al. Guidelines
for the diagnosis and
management of cow’s
milk protein allergy in
infants. Arch Dis Child
2007; 92: 902-8
Australian Consensus
Panel 2008
Kemp AS, Hill DJ, Allen KJ, 
et al. Guidelines for the
use of infant formulas to
treat cow’s milk protein
allergy: an Australian 
Consensus Panel Opinion.
Med J Aust 2008; 188: 
109-12
In exclusively breastfed
infants, strict elimination
of the causal protein from
the diet of the lactating
mother should be tried
Elimination of cow’s milk
from the maternal diet
may lead to resolution of
allergic symptoms in the
nursing infant. If symp-
toms do not improve or
mothers are unable to par-
ticipate in a very restricted
diet regimen, alternative
formulas can be used to
relieve the symptoms
Breast-fed infants with
proven CMA should be tre-
ated by CM avoidance.
Continue breastfeeding
but avoid CMP in mother’s
diet (plus Ca2+ supple-
ment)
Breastfeeding may be con-
tinued, and recommenda-
tions are provided for eli-
minating maternal intake
of CM protein
Allergen elimination is
relatively easy in exclusi-
vely formula fed infants
eHF or SF (see infra) Mild-to-moderate CMA:
eHF 
When:
– The child refuses to
drink eHF, but accepts AAF
– Symptoms do not
improve on eHF after 
2-4 weeks
– Cost-benefit ratio favo-
urs the AAF
AAF
Severe CMA
Refer to a paediatric spe-
cialist. 
In the meantime, an elimi-
nation diet should be star-
ted with AAF
–
Not to be used for treat-
ment of CMA
Not intended to be used
to treat CMA –
No place for pHF (known
as HA) in treating CM
Extensively hydrolyzed
protein is recommended
for the treatment of
infants with cows’ milk
protein allergy
At least 90% of CMA
infants tolerate extensive-
ly hydrolyzed formulas
Some eHF based on whey
and casein met the crite-
ria to be considered a the-
rapeutic formula: tolerated
by at least 90% (with 95%
confidence) of CMA
infants
Appropriate for treating
CMA
Type of feeding
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Soy formula (SF)
Other milks
Soy hydrolyzed 
formula (HSF)
Rice hydrolyzed 
formula (HRF)
Amino acid  
formula (AAF)
Formulas based on intact
soy protein isolates are
not recommended for the
initial treatment of food
allergy in infants
Although soy formulas are
not hypoallergenic, they
can be fed to infants with
IgE-associated symptoms
of milk allergy, particularly
after the age of 6 months
Are not hypoallergenic.
Significantly cheaper, bet-
ter acceptance than eHF
and AAF, but high risk of
soy allergy particularly 
< 6 months.
High concentration of phy-
tate, aluminium and phy-
to-oestrogens (isoflavo-
nes), possible undesired
effects
Appropriate for treating
CMA
CMA children should not
be fed preparations based
on unmodified milk of
other species (such as
goats’ or sheep’s milk)
because of a high rate of
cross-reactivity
Milk from goats and other
animals or formulas conta-
ining large amounts of
intact animal protein are
inappropriate substitutes
for breast milk or cow’s
milk-based infant formula
The use of unmodified
mammalian milk protein,
including unmodified
cow’s, sheep, buffalo, hor-
se or goats’ milk, or
unmodified soy or rice
milk, is not recommended
for infants
There is no place for other
mammalian milks (such as
goats’ milk) in treating
CMA
Extensively hydrolyzed
protein is recommended
for the treatment of
infants with cows’ milk
protein allergy (non-speci-
fied if also HSF)
–
eHFs based on another
protein source met the cri-
teria to be considered 
a therapeutic formula:
tolerated by at least 90%
(with 95% CI) of CMA
infants (HSF not expressly
cited)
–
At the time of recommen-
dations, not extant
At the time of recommen-
dations, not extant
eHFs based on another
protein source met the cri-
teria to be considered 
a therapeutic formula:
tolerated by at least 90%
(with 95% CI) of CMA
infants (HRF not expressly
cited)
At the time of recommen-
dations, not available in
Australia
Are considered to be non-
allergenic. Highly sensitive
patients (i.e., patients
reacting to eHF) may requ-
ire an amino acid based
dietary product
Tolerated AAF met the criteria to be
considered a therapeutic
formula: tolerated by at
least 90% (with 95% CI) of
CMA infants
Appropriate for treating
CMA
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Table 21. cont.
Differentiation 
of recommen-
dations by 
phenotype
Formula to be 
given during 
the diagnostic 
elimination 
phase
Anaphylaxis
ESPACI/ESPGHAN 1999
No, only IgE mediated vs. 
non-IgE-mediated, but the
recommendations do not
differ
AAP 2000
Infants with IgE-associated
symptoms of allergy may
benefit from a soy formu-
la, after 6 months of age
(eHF before 6 months).
Non-IgE-associated syn-
dromes such as enteroco-
litis, proctocolitis, malab-
sorption syndrome, or
oesophagitis – eHF
No. Scientific Society 2007*
–
Australian Consensus
Panel 2008
< 6 months: eHF for
immediate CMA (non-ana-
phylactic), FPIES, atopic
eczema, gastrointestinal
symptoms and food prote-
in-induced proctocolitis
> 6 months: SF for imme-
diate reactions, GI symp-
toms or atopic dermatitis
in the absence of failure
to thrive
AAF 1st choice in anaphyla-
xis and eosinophilic oeso-
phagitis
– –
Mild-to-moderate CMA: 
eHF or AAF
Severe CMA: AAF –
eHF
SF (no specific indication
for anaphylaxis, only for
IgE-mediated CMA)
–
AAF
Immediate GI 
eHF
SF 1st, eHF 2nd – eHF < 6 months, 
reactions AAF > 6 months
IgE-mediated SF 1st, eHF 2nd eHF < 6 months, 
respiratory eHF – AAF > 6 months
reactions
IgE-mediated SF 1st, eHF 2nd eHF < 6 months, 
cutaneous eHF – AAF > 6 months
reactions
Atopic SF 1st; eHF 2nd? eHF < 6 months, 
dermatitis eHF No specific – AAF > 6 months
recommendation 
Delayed GI eHF: “In infants with eHF < 6 months,
reactions adverse reactions to AAF > 6 months
food proteins and 
malabsorptive enteropathy, AAF in eosinophilic
the use of a formula with oesophagitis
highly reduced allergenicity 
(extensively hydrolyzed 
eHF formula or amino acid –
mixture) without lactose 
and with medium chain 
triglycerides might be useful 
until normal absorptive 
function of the mucosa 
is regained”
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Heiner eHF? No specific eHF? AAF? 
syndrome eHF recommendation – No specific
recommendation
Follow-up Controlled re-challenges 
should be performed 
at regular intervals – – –
to avoid unnecessarily 
prolonged avoidance diets
*Company-supported guidelines intended for general paediatricians and/or GPs. Recommendations valid for mild to moderate CMA. In case of suspicion 
of severe CMA, refer to a specialist
sibility of allergy to hydrolysed casein or whey proteins
of cow’s milk, obtained by extensive hydrolysis and used
in milk substitutes (eHF formulas). Allergy to hydrolysates
is sometimes the cause of the absence of clinical improve-
ment in patients with atopic dermatitis, refractory gas-
troesophageal reflux, lack of weight gain, or multiple food
allergy, treated with these formulas. These patients should
receive an amino acid formula (AAF), in which the protein
fraction is replaced by a set of synthetic amino acids. The
validity of any such therapeutic-nutritional change is con-
firmed by a positive result of the test for specific IgE
against casein or whey fractions of cow’s milk proteins.
Where these tests are not available, ex juvantibus treat-
ment should be considered [63, 105].
To avoid unnecessary dietary treatment, every treat-
ed child with clinical improvement, after a period of using
the elimination diet (minimum 6 months), should be
assessed for the acquisition of tolerance of the initially
harmful food. This is usually achieved by performing
a food challenge test with the previously eliminated food
[10, 14, 59, 66, 74-84].
It must be remembered that dietary treatment of food
hypersensitivity may be associated with some risks. One
of them is unjustified, unwise (and therefore unpre-
dictable in its consequences) elimination of a specific food
from the previously used diet of the patient. This pre-
caution applies to those persons (children/adults) who
used to consume a certain product (products) without
any clinical signs of hypersensitivity to this food (e.g. chil-
dren with atopic dermatitis). Parents of children or adult
patients who have positive results of allergy tests (PST,
sIgE), showing only “sensitization” of the body (e.g. to
allergens contained in chicken egg proteins or fish), which
is not causally related to the allergic condition, often take
an unjustified decision to temporarily eliminate the prod-
ucts containing these allergens from the patient’s diet.
The use of an elimination diet for a limited time in these
patients can paradoxically result in loss of previously
existing tolerance to the allergen tested. A repeated expo-
sure to the eliminated allergen (accidental or deliberate
consumption) can trigger serious symptoms of an aller-
gic reaction, including shock [106-109]. Nutritional-ther-
apeutic formulas containing partially hydrolyzed protein
fraction of cow’s milk (casein, whey proteins) (partially
hydrolyzed formula – pHF) are not recommended for the
treatment of allergy to cow’s milk. They should be used
solely for the prevention of the development of allergic
processes [10, 59]. The guidelines concerning the appli-
cation of different nutritional formulas, including milk of
certain ungulates (sheep, goat, buffalo, camel) and milks
based on vegetable protein (rice, almonds, soy), in the
treatment of patients with allergy to cow’s milk protein
contains Table 21 [11]. The rationale for limited therapeutic
use or the lack of indications is the possibility of cross-
reactivity with cow’s milk proteins; moreover, some of
these products used as a single nutrient do not provide
a sufficient source of protein coverage for the treated
patients (Table 21) [10, 11, 98-100].
Summary 7
Food hypersensitivity is a clinical condition in which
harmful food is the major cause of the disease. The basis
of treatment is the elimination diet, which consists in
temporary removal of the harmful food from the patient’s
diet, with simultaneous introduction of replacement com-
ponents with equivalent nutritional value in place of the
eliminated food or group of foods.
Measures of the therapeutic efficacy of an elimina-
tion diet include complete or partial resolution of clinical
symptoms, improvement of the patient’s general condi-
tion, normal physical development (weight gain, growth)
and psychomotor development of the paediatric patient.
To meet the expected therapeutic requirements, an
elimination diet should be individually selected with con-
sideration of the type of harmful food, qualitatively and
quantitatively adjusted to the patient’s age, taking into
account the progress of the disease and the necessary
time of its therapeutic application.
Careless or reckless use of an elimination diet in
patients with laboratory-confirmed allergy to specific anti-
gen(s) who have no symptoms of an allergic disease may
result in loss of previously existing immune tolerance to
this antigen. The reintroduction of the temporarily elim-
inated food (allergen) into the diet can trigger symptoms
of allergic disease, including anaphylactic reaction.
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In everyday clinical practice we meet patients who
rapidly “grow out” of food allergies, without using a strict
elimination diet, as well as those who do not lose their
hypersensitivity to the harmful food, despite using a strict
diet.
The extensively hydrolyzed milk replacement products
(eHF formulas), the elementary AAF formulas, soybean
formulas and nutritional formulas enriched with MCT, pro-
biotics, prebiotics, and LC-PUFA, adjusted for age (both
qualitatively and quantitatively balanced), may be used
in children with food hypersensitivity. A milk free elimi-
nation diet including these products must enable normal
physical and psychomotor development of the treated
child.
Acquisition of tolerance to initially harmful food
(“outgrowing” food allergy)
In accordance with the principle that the therapeutic
diet cannot be more troublesome than the primary dis-
ease, the patient treated using this method should peri-
odically undergo a food challenge test. This test allows
one to assess the ability of the paediatric patient’s body
to acquire tolerance to the eliminated food [10, 11, 14, 59,
66, 74-92, 110, 111]. Everyday clinical observations show
that a significant number of children with allergic reac-
tions to consumed foods begin to tolerate it with time,
usually within 2-3 years after diagnosis of the disease
and starting the appropriate treatment [11, 14, 112-114].
This phenomenon is also supported by immunological
studies. Immune tolerance is antigen-specific suppres-
sion of humoral and cellular response of the body, occur-
ring as a result of previous oral exposure to an antigen.
In the clinical meaning, it is the lack of response to expo-
sure to the causative antigen, even after a long period
without any contact with the antigen [110, 111]. This phe-
nomenon is also referred to as “outgrowing” food aller-
gy; it involves the loss of hyperreactivity of the body to
most previously sensitizing allergens (protein of cow’s
milk, eggs, soybean and others). In approximately 85% of
patients this process takes place in the first years of life.
Based on observations in selected clinical centres it can
be concluded that the appearance of tolerance in hyper-
sensitivity to these commonly consumed food products
is more common in people without specific antibodies
(sIgE) against these foods in allergy tests [54, 55, 57, 58,
112-114]. They “outgrow” their hypersensitivity faster and
in a higher percentage compared to atopic patients who
longer maintain IgE against food allergens and the dis-
ease process becomes persistent [112-114].
The studies of Høst et al., evaluating the process of
tolerance development among children with allergy to
cow’s milk proteins, showed that it is acquired more
rapidly by children whose symptoms were mediated by
non-IgE mechanisms, as compared to children with IgE-
mediated allergy. Patients with IgE-mediated allergy to
cow’s milk were characterized by a tendency to a persis-
tent disease process; over time, these children addition-
ally developed other allergy symptoms (respiratory aller-
gy) (Table 22) [14].
In other studies of Høst et al., 56% of children aller-
gic to cow’s milk proteins acquired tolerance to milk and
dairy products by 1 year of age, 77% by 2 years, 87% by
3 years, 92% between 5 and 10 years, and about 97% by
15 years [112].
The development of tolerance to cow’s milk proteins,
with consideration of the pathogenetic mechanism of
allergy, was the aim of the study conducted by Vanto et
al. among Finnish children (Table 23) [113].
The results of these studies confirm that the toler-
ance acquisition process is faster and occurs in a higher
proportion of children with allergy to cow’s milk proteins
when non-IgE mediated mechanisms are involved [113].
Persistent allergy to cow’s milk proteins was also con-
firmed in studies conducted among Portuguese children
by Santos et al. [114]. In comparison to the overall study
group, in the subgroup of children with IgE-mediated aller-
gy to cow’s milk proteins, the tolerance acquisition
process occurred significantly later. This is depicted by
the following data: by 2 years of age, tolerance was
acquired by 34.0% of the whole group vs. 0.0% of chil-
dren with IgE-mediated allergy; by 5 years of age – 55.0%
vs. 22.0%; by 10 years of age – 68.0% vs. 43.0%. Most of
the children from the group with symptoms of allergy to
cow’s milk proteins (73%) demonstrated clinically more
than one symptom: skin (81%), gastrointestinal tract
(55%), respiratory system (16%) or a systemic reaction
(shock) (3%). Children with IgE-mediated allergy had high-
er values of immunological parameters (PST, sIgE) com-
pared to the entire study group. The IgE-mediated patho-
genetic mechanism of their hypersensitivity, along with
clinical picture of the disease (including asthma) and high
values of allergic and immune markers of this process,
were considered in these children to be independent and
Table 22. Prognosis of cow’s milk protein allergy [14] 
Study type % Recovery % Allergy to other food % Inhalant allergy 
Prospective unselected (0-3 years) 84-87 54-60 28* 
Prospective selected (2-4 years) 33-38 41-75 40-43** 
*Among infants with CMA (IgE-mediated reactions) 48% have developed inhalant allergy by 3 years of age, **In one study 80% developed inhalant allergy 
before puberty
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negative predictive factors, delaying the process of
immunological tolerance acquisition [114, 115].
Three main immune mechanisms are involved in the
emergence of food tolerance: clonal anergy, clonal dele-
tion and active suppression. They may occur simultane-
ously or independently in the same organism, and the
main factor determining the type of the leading mecha-
nism is the nature of the antigen (soluble, solid), its dose
and the frequency of administration. Using high doses of
the antigen results in the development of food tolerance
through clonal deletion or anergy; small doses of the anti-
gen generally induce active suppression, associated with
the role of regulatory T lymphocytes (Treg) [116-118].
Summary 8
Most children with food hypersensitivity, diagnosed
and treated during infancy or early childhood, “outgrow”
the disease over time (about 80% by the age of 4-5 years).
In the remaining patients, the state of persistent food
hypersensitivity is individually varied over time.
The process of “outgrowing” food hypersensitivity is
determined by several factors, of which the following
should be considered the most important: the child's age
at the time of the diagnosis and initiation of treatment
(including the elimination diet), severity of disease symp-
toms and pathogenetic mechanisms that trigger them
(IgE-mediated, non-IgE mediated, mixed, cellular), posi-
tive family history of atopy and/or allergy.
The ability to acquire tolerance to previously harmful
food occurs earlier and in a higher percentage of patients
with non-IgE mediated food hypersensitivity compared
to patients whose symptoms are triggered by an IgE-
mediated (atopic) pathogenetic mechanism.
Drug therapy and other treatment options 
of food hypersensitivity
Pharmacological treatment is a “complement” of com-
prehensive therapy of food hypersensitivity states, in cas-
es where dietary measures alone appear to be ineffective
or inadequate. 
Pharmacological treatment of food hypersensitivity
includes both immediate and long-term management.
The immediate procedure is to fight short-term clinical
symptoms of an ongoing or already developed post-feed-
ing allergic reaction. If the reaction is shock, then this pro-
cedure involves the control of life-threatening symptoms,
in the first place to administer first aid drugs, including
epinephrine (auto-syringe). It is vital to educate the fam-
ily and caregivers (teachers) of a sick child who is expe-
riencing this type of reaction about the principles of first
aid and the nature of allergic disease. In fact, such a reac-
tion may occur both at home and outside the home
(kindergarten, school, excursion, restaurant) [119-121].
Long-term pharmacological treatment involves the
administration of anti-allergic drugs for prevention. It
aims to prevent a recurrence or relapse of allergic disease.
In the pharmacological treatment, various agents are
available with a different potency, different mechanisms
of receptor interaction, administered in various forms and
using various routes to the patient’s body. Their proper
selection, taking into account the pharmacological and
pharmacodynamic properties and clinical manifestations
of food allergy (single-organ, multiple-organ) determines
the effectiveness of this therapy in hospital and outpa-
tient treatment. However, no drug, even the most effec-
tive one, can replace causal treatment of food hypersen-
sitivity, that is, temporary elimination of the harmful food
from the patient’s diet. The drugs available on the Polish
market are widely used to fight symptoms of food hyper-
sensitivity, both in acute and chronic phases of the dis-
ease (pharmacological prophylaxis). Drugs with systemic
and local action are used for this purpose, using their anti-
histaminic properties (classical H1 receptor blockers, 2nd
and 3rd generation antihistamines); antihistamines and
anti-allergic; anti-inflammatory (steroids); antileukotriene;
and others (biological drugs, calcineurin inhibitors).
In the case of life threatening food reactions (ana-
phylactic shock), the recommended anti-shock procedure
should be implemented immediately (auto-syringe with
epinephrine) and the patient should be transferred for
further treatment to a hospital [8, 10, 11, 28, 33, 50, 66,
92, 100, 119-121].
A better understanding of the allergic process, owing
to advances in the fields of molecular biology and clini-
cal immunology, opens up new prospects for treatment
of food hypersensitivity. They are based on the principle
of causing a change in immune responses, in people sen-
sitive to the harmful food, from the state of “hyperreac-
tivity” to “hyposensitivity”. Attempts are made to treat
patients with food allergy using methods of broadly
understood “immunomodulation”. One of these meth-
ods is oral immunotherapy (OIT), considered a method
alternative to the elimination diet in the treatment of food
allergy [122-124]. It involves oral or sublingual adminis-
tration of allergens (sublingual immunotherapy – SLIT) in
increasing doses (for months or years) with simultane-
ous monitoring of clinical symptoms and immunological
markers. This method can only be applied to certain IgE-
Table 23. Development of tolerance to cow’s milk proteins
in children with cow’s milk hypersensitivity depending on
the pathogenetic mechanism of reaction [113]
Age [years] Mechanism Mechanism 
IgE mediated non-IgE mediated 
(immediate reaction) (delayed reactions) 
2 31.0% 64.0%
3 53.0% 92.0%
4 63.0% 96.0%
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mediated allergic conditions such as allergy to cow’s milk
proteins, chicken egg proteins and nuts (peanuts, hazel-
nuts). Sublingual immunotherapy has been used to treat
cross-allergies in people allergic to birch pollen and
responsive to apples. Skripak et al. desensitised for
4 months a group of 20 children with IgE-mediated aller-
gy to cow’s milk proteins using increasing doses of the
allergen, and compared the results to a group of 20 chil-
dren treated with an elimination diet alone (placebo
group). The conclusion of this study was that “compared
to placebo, immunotherapy with milk resulted in various
degrees of desensitization in the treated group of
patients” [123].
A methodological variant of this therapy is specific
induction of food tolerance by the patient’s contact with
a thermally processed harmful allergen (specific oral tol-
erance induction – SOTI) [125, 126]. This method induces
tolerance in allergy to cow’s milk proteins or chicken egg
proteins. The effect of tolerance is transient and does not
necessarily lead to “persistence” of the process. Constant
supply of the allergen is required to maintain the obtained
status as an interruption in its supply usually results in
loss of the therapeutic effect achieved so far [125, 126].
It should be noted that oral immunotherapy is not yet
an approved method of treatment for IgE-mediated food
allergy, although it appears to be effective in obtaining
“desensitization” in a certain group of patients. There is
also no clear opinion as to whether this method can lead
to long-term tolerance, in which form the allergen should
be introduced into the body (soluble or solid), and how
safe is this therapeutic method [123-126]. Further research
is needed on new opportunities for the treatment of food
hypersensitivity and prophylactic and/or therapeutic mea-
sures using specific bacterial strains showing probiotic
properties, prebiotics, LC-PUFA, and vitamin D, which can
create better opportunities than ever to comprehensive-
ly help patients with food hypersensitivity [11, 127-130].
Summary 9
Pharmacological treatment is complementary to com-
prehensive treatment of food allergy and should be used
temporarily to control the rapidly increasing allergic symp-
toms. Long-term pharmacological treatment used along
with dietary therapy should be used when dietary treat-
ment alone does not produce the desired effects in the
form of clinical improvement.
No drug, even with high temporary efficacy, can sub-
stitute causal treatment of food allergy, that is, tempo-
rary elimination of the harmful food from the diet of the
paediatric or adult patient.
New therapeutic opportunities for IgE-mediated food
allergy include oral immunotherapy and sublingual
immunotherapy with a native food allergen, or specific
“desensitization” of the sensitized organism using ther-
mally processed food allergen.
Preventive actions in food hypersensitivity
Preventive and prophylactic measures in food hyper-
sensitivity consist in protective activities in patients in
whom the risk of atopic or allergic disease is possible or
highly probable (positive family history, atopic or allergic
constitution, exposure to adverse environmental and
infectious factors) [33, 41, 130-133].
Preventive actions, carried out in a comprehensive
manner, are targeted at the general public or selected
groups, which include people with an increased risk of
developing allergies, or patients with symptoms of aller-
gic diseases [11, 132, 133]. These activities fall within con-
cepts of primary prevention (preventing the sensitization
in a person predisposed to atopy or allergy, who has not
yet come into contact with a potentially harmful antigen).
Secondary prevention means preventing the allergic dis-
ease development in a “sensitized” person, or subsequent
relapse of symptoms of an already developed allergic 
disease. Tertiary prevention means protecting against
progressive damage of organs affected by the allergic 
disease [51, 131-133].
Feeding a child in infancy and early childhood is the
primary area of activities involved in primary prevention
of food allergy. One of the key activities is to promote
natural breast-feeding for at least the first 4-6 months
of life. Natural nutrition during this period, as compared
to artificially fed infants (with a milk replacement 
formula), reduces the incidence of atopic dermatitis, and
the risk of allergies to milk protein  in children during the
first 2 years of life. After  reccomended  breast feeding
period, the diet of infants or small children should be
gradually enriched in new products, including potential-
ly allergenic foods (meat, egg white, cereals, fish, soy,
fruits, vegetables and other products) (Table 24) 
[134-140].
An inherent part of these activities is also rational
nutrition of women during pregnancy and lactation 
(a qualitatively and energetically balanced diet). In the case
of mothers belonging to the so-called group of increased
risk of allergy, an individually selected hypoallergenic diet
in a breast-feeding mother can be effective as a preven-
tive measure. For pregnant women, the preventive effect
of such a diet has not been clearly demonstrated,
although there is clinical evidence for the possibility of in
utero sensitization of a child by foods consumed by
a pregnant woman [136-141]. There is controversy as to
intrauterine sensitization, as exemplified by the studies
of Rowe et al. These authors challenged in their studies
the concept of early, prenatal sensitization, as well as pro-
viding evidence that sensitization occurs only after birth,
during early childhood. These authors observed a group
of 200 children born in families with a high risk of aller-
gies; specific IgE and IgG4 antibodies and cytokine pro-
file (IL-4, IL-5) of mononuclear cells against selected food
allergens (including chicken egg protein and cow’s milk
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Table 24. Maternal and infant diets for prevention of allergic diseases – guidelines [140]
Definitions/ Group/publication
interventions
AAP 2008 AAP 2000 ESPACI/ESPGHAN 1999, SP-EAACI,
Clinical Report Recommendations ESPGHAN 2008 2004, 2008
Recommendations Recommendations
Risk category: Parent or sibling with Biparental or parent plus Parent of sibling Parent of sibling with 
“high risk” documented allergic disease sibling history of allergy affected (1999) documented allergic disease
Pregnancy Lack of evidence Possible peanut
–
No special diet*
avoidance
Breast feed Evidence for 3-4 months 6 months 4-6 months* At least 4 months, 
“exclusively” (wanting 4-6 months tied prefer 6 months*
until to introducing solids)*
Maternal Some evidence for Peanuts, tree nuts No special diet*
lactation reduced atopic and “consider” egg, –
avoidance dermatitis milk, fish, and “perhaps 
of allergens other foods” 
Prevention Compared with whole “Hypoallergenic formula” Confirmed reduced Extensively hydrolysed
formulas cow’s milk protein, (extensive hydrolysate, allergenicity (1999) until 4 months
evidence for certain possible partial of age (2004); documented
extensive hydrolysates (eHF), hydrolysate); not soy educed allergenicity (2008)
partial hydrolysates (pHF), 
but not soy
Types Evidence to wait Solids held to 6 months Not before 17 weeks and No evidence of diet 
of “solids” and for 4 (to 6) months; Diary products, age 1 years no later than 26 weeks; effect after 4-6 months
complementary lack of convincing Egg, 2 years no convincing evidence 
foods evidence for avoiding Peanuts, nuts, fish, for delaying potentially 
specific allergenic foods age 3 years allergenic foods such 
as fish, egg (2008)*
*Advice that is the same for those not “high risk”, AAP – American Academy of  Pediatrics, ESPACI – European Society for Pediatric Allergology and Clinical 
Immunology, ESPGHAN – European Society for Paediatric Gastroenterology, Hepatology and Nutrition, SP-EAACI – Section on Pediatrics, European Academy
of Allergology and Clinical Immunology
proteins) and airborne allergens (house dust mite) were
determined after birth (cord blood and at 6, 12, 24 months
of age). The dynamic behaviour of these antibody titres,
with a downward trend in their concentrations in the age
range of 0 to 24 months, indicates that this is the period
when tolerance develops (“time window”). Contact with
allergens in this age range may promote the induction of
immune tolerance in a given child [142].
The overall context of prophylactic measures against
food allergies also includes the appropriate use of thera-
peutic-nutritional formulas (cow’s milk protein hydrolysates,
other hypoallergenic formulas) [136-141, 143-147]. This
category of activities also includes the use of anti-aller-
gic drugs and antihistamines [100], probiotics and prebi-
otics, LC-PUFA, vitamin D, eliminating the risks associat-
ed with exposure to tobacco smoke and other airborne
and contact allergens, and infections [127-130, 148-151].
These measures should be complemented with broad
educational activities for the patient and his environment
(family, nursery, kindergarten, school, workplace, etc.)
[152-158]. More clinical studies and new data are neces-
sary to assess long-term outcomes of early dietary inter-
vention, and the use of probiotics, prebiotics, omega-3
acid, and vitamin D during infancy, to prevent the devel-
opment of allergic and infectious diseases later in life
(youth and adulthood) [149-152].
Summary 10
Preventive and prophylactic activities in the context
of allergy development must be carried out in relation to
children belonging to risk groups, i.e. those who have
a positive history of atopic or allergic disease in their par-
ents, siblings or other relatives.
Preventive measures (primary prevention of allergy)
consist in comprehensive prevention of sensitization of
the organism. These relate to the pre-conception, prena-
tal and postnatal periods. An important role in the post-
natal period (infancy and early childhood) can be attrib-
uted to the correct nutrition of the child, avoiding
exposure to selected allergens, and avoiding exposure to
some other harmful environmental factors (e.g. tobacco
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smoke). Secondary prevention consists in prevention of
recurrence of allergic disease, after the first occurrence
of clinical symptoms. Tertiary prevention means protect-
ing against progressive damage of organs affected by the
allergic disease resulting from its chronicity and recur-
rence.
The preventive and prophylactic measures in the
group of patients at risk of developing an allergy should
be comprehensive and include:
– general promotion of natural breast-feeding of infants
during the first 4-6 months of life;
– introduction of solid non-milk products (including gluten
products) in the infant’s diet no earlier than 4 months
and no later than 6 months of age;
– introduction, after 6 months of age, of nutritional prod-
ucts considered highly allergenic (milk, eggs, soy, fish)
probably does not increase the incidence of atopic dis-
eases; it is even believed that delaying such a diet may
promote the development of these diseases.
There is no evidence that cow’s milk protein
hydrolysates, used preventively in infants at risk of devel-
oping an allergic process, are superior to natural feeding.
Protein hydrolysates, used in the prevention, are superi-
or to milk replacement formulas used in infant feeding.
They can prevent the occurrence of AD or delay its devel-
opment; however, the final effect depends on the degree
of protein hydrolysis (eHF, pHF formulas).
There is insufficient evidence regarding the preven-
tive value of amino acid formulas (AAF) in the develop-
ment of atopic diseases.
Dietary restrictions implemented by pregnant women
have not yielded satisfactory results in reducing the preva-
lence of atopic diseases in their children.
The elimination of certain food products from the diet
of a breast-feeding woman during lactation (justified by
the presence of food allergens in her milk) induced a ben-
eficial effect only among infants with atopic dermatitis.
The assessment of the effectiveness of a diet enriched
in probiotics, prebiotics, LC-PUFA, vitamin D and other
ingredients (milk or milk replacement formulas), used in
infants and young children, in the prevention of allergic
and infectious diseases, requires further research and
clinical trials.
Social and economic aspects of food allergy*
According to the Allergy White Paper of the WAO
(2011), allergic diseases affect about 30-40% of the glob-
al population [159]. Due to the increasing prevalence, they
occupy a significant place among other chronic diseases
and are a public health problem in the developed coun-
tries [159-163].
Food allergy, like other allergic diseases, is a chronic
disease of children, adolescents and adults, with a preva-
lence estimated by the WHO to be around 3% to 8%
among children and about 1% to 3% in the adult popula-
tion [7]. The WAO Allergy White Paper indicates that 
220 to 520 million people in the world are affected by this
condition [159]. In Poland, food allergy is included in the
list of chronic, congenital or acquired diseases, for which
drugs and medical devices are prescribed free of charge,
for a flat or partial payment [164].
Due to the scale of the problem, many countries have
started studies aimed at assessing the social and eco-
nomic effects of food allergy, in terms of both the nega-
tive impact of the disease on the quality of life of patients
and their families, and the generated costs, including the
significant impact of the cost of treating allergies to cow’s
milk on the overall financial resources allocated to health
care in some countries. This issue has been the subject
of several publications [154, 165-174].
An international research project, EuroPrevall, is
focused on multi-faceted problems of food allergy in the
European Union. One of its main topics of research focus-
es on assessing the socio-economic impact of food aller-
gy [171, 173, 174].
In the opinion of the participants of this project, the
social impact of this disease in European society may be
much greater than previously thought; it affects the dif-
ferent spheres of life of the patients and their families,
reducing their quality of life [171, 173].
The group of researchers implementing the project
drew attention to the fact that the economic costs of food
allergy are borne at different levels of functioning in soci-
ety, by both public and private organisations. The
researchers pointed to several “stakeholders” incurring
the costs of this disease: consumers (mostly patients and
their families), food industry (manufacturers and food
processors, retail, catering firms and restaurants), health
and social care (hospitals, specialist clinics and primary
care outlets, diagnostic laboratories, welfare – mostly ben-
efits), carers and care institutions (parents and relatives,
schools, kindergartens, nurseries, non-governmental orga-
nizations), employers, institutions and agencies dealing
with legal regulations and control (local and internation-
al) [171]. The direct costs of the disease, borne by indi-
viduals (patients or their caregivers) and households (fam-
ilies), are mainly related to special feeding and care of
sick children, treatment and transport to the doctor, as
well as the search for relevant information about the dis-
ease. The direct costs incurred by the public sector are
mainly related to the provision of health care to these
patients (expenses for health services, including medi-
cines) [165, 171, 174]. The indirect costs borne by patients
(parents of sick children) are measured in terms of lost
opportunities, including the time necessary for the use
of medical care, seeking information about the disease,
lost possibility of gainful employment by the patient or
his guardians (sick leave or resignation from work), and
lost opportunity to rest. In the category of non-quantifi-
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able costs of the disease, the quality of life of patients
and their families has been assessed [171, 173, 174]. The
results of studies on food allergy social impact suggest
a number of adverse phenomena, disrupting the daily
activities and social contacts of the patient (sick child)
and his family (difficulties arising from the recommend-
ed elimination diet, and stress associated with the risk
of a dietary mistake). The consequence is a significant
reduction in the level of quality of life of patients and their
families, as well as a negative impact on the psycho-emo-
tional and physical development of children suffering from
the disease [154, 167-171, 173].
The need to continue this type of research and to dis-
seminate the results in society involves the requirement
for broader educational activities, not only for the patient
and his family, but also all those public and private organ-
isations that have a direct and indirect effect on the health
of the individual and society [158, 171-173, 175].
In some countries, both state institutions dealing with
public health problems, such as scientific societies, and
organisations of patients and their families, have taken
actions aiming to reduce the negative effects of food aller-
gy. The problems related to food allergy were analysed
and educational activities have been started, aimed at
both the patients and their families, and the medical com-
munity. An example of such activities is the development
of uniform guidelines regarding the diagnosis and treat-
ment of food allergy, preceded by a thorough analysis of
available studies worldwide. These guidelines are pub-
lished on public websites, sometimes in two versions –
for physicians and health care professionals, and for
patients or their parents; there are also many educational
websites addressed at sick children and their caregivers
[4, 11, 120, 139, 176-179].
These problems seem to be still underestimated in
Poland. The only position on allergy and food intolerance
available to date, developed by a Polish group of experts,
was published in 1997 [180].
Summary 11
Chronic diseases, including allergic diseases, are char-
acterized by long duration, recurrence and disruptive
symptoms. In the perspective of health care financing,
the situation of the patient, his family and the environ-
ment, chronic disease is a serious socio-economic prob-
lem.
These diseases include food allergy, which lowers the
quality of life of the sick child or adult patient and their
families, impacting negatively on the psycho-emotional
state of the patient and interfering with his/her social
contacts.
Food allergy also generates economic costs incurred
by different entities (public and private) participating in
social life.
Direct costs of the disease are borne by both patients
and their families (expenses related to special feeding
and care of sick children, treatment, travel, searching for
information about the disease), and by the public sector
(expenditure on health services and medicines). The indi-
rect costs incurred by the patients themselves or parents
of these children are measured in terms of lost opportu-
nities (time lost for the use of medical care, seeking infor-
mation about the disease, lost possibility of gainful
employment, lost opportunity to rest). The indirect costs
borne by the public sector are mainly related to costs of
lost productivity and expenditures in the sphere of social
security.
An immeasurable cost of the disease is the reduced
quality of life of the patients and their families.
To reduce the socio-economic costs of food allergy, it
is necessary to implement educational activities to pro-
mote knowledge about proper diagnosis of the disease
and the principles of treatment (primarily an elimination
diet). They should be addressed at: the parents of sick
children, adult patients, their families, professional staff
involved in health care and education, people and insti-
tutions involved in the production and distribution of food
and nutrition, as well as the staff of the institutions of
care and education.
The relationship between chronic disease, such as
food allergy, and the quality of life of patients and the
costs generated by the disease, borne by both patients
and their families and the economy, should be the sub-
ject of prospective studies in our country. It is also advis-
able to undertake educational activities addressed at var-
ious groups of society.
Glossary of terms used in the text
AAF (amino acid formula) – a milk replacement for-
mula in which the protein fractions were replaced by a set
of synthetic amino acids.
Active immunosuppression – inhibition of cell activi-
ty by interactions with other cells producing suppressive
cytokines, or idiotypically specific lymphocytes that rec-
ognize the receptors for a specific antigen.
Adverse reaction to foods – repeatable and repro-
ducible clinical symptoms, occurring in some people
(regardless of age) after intake of food(s) or food additives.
Allergen – a substance with the characteristics and
properties of an antigen, potentially harmful to those per-
sons in whom it induces a state of sensitization.
Allergy – a manifestation of hypersensitivity with
a specific immune response to a specific allergen. The
nature of allergy is the qualitatively altered reactivity of
the tissues of the body, based on the antigen-antibody,
or antigen-immunocompetent cell reactions.
Anaphylaxis – antigen-specific immune response, pri-
marily mediated by IgE antibodies. It is a life-threatening
reaction due to rapid vasodilation (pressure drop), and
smooth muscle contraction (including those in the bronchi).
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Antigen – a substance foreign to the body, causing
the development of a specific immune response, i.e. anti-
bodies interacting with immunocompetent cells through
specific receptors located on these cells.
Antigen presentation – the process by which certain
cells of the body (antigen presenting cells) present an
antigen on their surface so that it can be recognised by
lymphocytes.
Antigen processing – the conversion of an antigen to
a form that can be recognised by immunologically com-
petent cells.
Atopy – a genetically determined (individual or famil-
ial) immune response, involving the capacity of the body
to systematically produce sensitising IgE antibodies, after
exposure to an usual dose of an environmental allergen.
Clinical tolerance – lack of the body’s response to
exposure to the causative antigen, even after long peri-
ods of abstinence.
Clonal anergy – the state of non-reactivity of T-cells,
which are not capable of an effective immune response
despite exposure to the antigen.
Clonal deletion – the elimination of specific clones of
lymphocytes at some stage of their maturation.
Cross-allergy – simultaneous hypersensitivity to food,
airborne or contact allergens with a homologous amino
acid sequence, especially within the epitopes.
Cytokines – a basic term for soluble molecules that
mediate reactions between cells.
Cytotoxic effect – the ability to kill cells.
DBPCFC (double-blind, placebo-controlled food chal-
lenge) – a double-blind food challenge test with the use
of placebo.
eHF (extensively hydrolyzed formula) – a milk replace-
ment formula with a high degree of hydrolysis of the pro-
tein fraction.
HRF – rice hydrolyzed formula, a milk replacement 
formula based on extensively hydrolyzed rice protein.
HSF – soy hydrolyzed formula,  a milk replacement for-
mula based on extensively hydrolyzed soy protein.
Epitope – a single antigenic determinant, a defined
sequence of amino acids in the polypeptide chain. Func-
tionally it is part of an antigen that combines with the
antibody paratope.
Food – a set of biologically active substances (com-
pounds, elements) that are important to human life, hav-
ing not fully understood physiological and metabolic func-
tions in the body.
Food allergy – a manifestation of hypersensitivity of
the body in the form of a broad spectrum of clinical symp-
toms (single- or multi-organ), caused by eaten food (food
allergen), which initiates and/or sustains an immune
response of the organism.
Food hypersensitivity – a manifestation of the inabil-
ity to generate and maintain immune tolerance of ingest-
ed food products or a “breach/collapse” of pre-existing
tolerance.
GALT (gut-associated lymphoid tissue) – lymphoid tis-
sue associated with the bowels.
Hapten – a small molecule that can act as an epitope,
but is not able by itself to elicit an antibody response.
Hypersensitivity – objectively reproducible symptoms
caused by exposure to a specific stimulus in a dose tol-
erated by healthy people.
Immune complex – the product of antigen-antibody
reaction, which may also contain components of com-
plement.
Immune specificity and memory – two features of
acquired resistance; the immune system responds more
effectively to a secondary or further contact with a given
antigen.
Immune tolerance – antigen-specific suppression of
humoral and cellular response of the body, occurring as
a result of previous oral, subcutaneous or mucosal expo-
sure to the antigen.
Immunogenic – having the ability to generate an
immune response, which involves, among others, T and
B lymphocytes.
Immunomodulation – the possible biological effects
on the body’s immune system via stimulation (immunos-
timulation), inhibition (immunosuppression) or actions
adjusting the immune reactivity (immunoregulation).
Immunotherapy – the administration of the causal
allergen to a sensitized organism, in increasing doses, at
appropriate time intervals and via the appropriate route
(oral, subcutaneous, sublingual), in order to desensitize
the body, which eventually leads to sustained immune
and clinical tolerance of a given allergen.
Interleukins – a group of molecules playing a role in
transmitting signals between cells of the immune system.
LC-PUFA – long chain poly-unsaturated fatty acids.
Ligand – a binding or joining molecule.
MALT (mucosal-associated lymphoid tissue) – lym-
phoid tissue associated with mucous membranes.
MCT – medium chain triglycerides.
Multiple food allergy – simultaneous hypersensitivity
to two or more food allergens.
OIT (oral immunotherapy) – oral administration of an
allergen in order to induce immune tolerance.
Pathogen – the organism that causes a disease.
pHF (partially hydrolyzed formula) – a milk replace-
ment formula with partial hydrolysis of the protein frac-
tion.
Primary immune response – (cellular or humoral), fol-
lowing the body’s first contact with a given antigen.
Priming – the primary cause of sensitization of the
body to an antigen.
PST (prick skin test) – test to measure specific IgE
attached to mastocytes in the skin.
RAST (radioallergosorbent test) – blood test to detect
specific IgE antibodies to suspected or known allergens.
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Receptor – a cell surface molecule that specifically
binds to a particular extracellular molecule.
Secondary immune response – after secondary or fur-
ther contact of the body with a given antigen.
SF – soy formula, a milk replacement formula based
on intact soy protein isolates.
Skin tests – skin reaction to injection or contact with
an antigen or allergen.
SLIT (sublingual immunotherapy) – sublingual admin-
istration of an allergen in order to induce immune toler-
ance in the body.
SOTI (specific oral tolerance induction) – the admin-
istration of a specific (processed) allergen to induce tran-
sient or permanent immune tolerance in the body.
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